September 29, 2005
Millenia Hope Collaborates With
Scientific Advisors
|
Source: Millenia Hope Inc.
Millenia Hope Generates First African MMH Malarex(TM) Sale
Wednesday August 10, 8:05 am ET
Milestone Sale First Portion of Larger Order
MONTREAL, Aug. 10 /PRNewswire-FirstCall/ -- Millenia Hope Inc., a Delaware Bio-pharma corporation (OTC Bulletin Board: MLHP - News; Berlin: MLF - News), today announced that it has sold, and has received payment of $200,000 for, 25,000 treatments of MMH Malarex(TM)/MMH 18(TM), to a chain of medical clinics in Western Africa. The purchaser also gave a $25,000 deposit for the next 25,000 treatments. This sale is the initial order in a contract that will generate sales of 100,000 treatments over the next 12 months.
There are 300-500 million malaria-infected individuals globally; three (3) million die annually, of which 1 million are children under five (5) years of age. An effective malaria cure is urgently needed. In many regions, 70% or more of malaria strains are resistant to existing medications and the World Health Organization (WHO) is no longer funding products like chloroquine to which malaria is resistant. MMH Malarex(TM)/MMH 18(TM) cures malaria in those regions where resistant strains are prevalent.
Leonard Stella, CEO, explained, "The WHO established, as one of its goals for the first decade of this new millennium, the reduction of malaria cases by 50%. Five (5) years into its mandate, this has not yet begun to happen, as the incidence of malaria is now worse than at the commencement of the year 2000. MMH Malarex(TM) has cured nearly 1,000 malaria sufferers in its various trials over the last five (5) years. We are saving lives right now! Contrary to the spurious and ill-considered opinions voiced in certain earlier articles, such as appeared in 2002 in the Scientist, Millenia and MMH Malarex(TM) are very real and scientifically safe and sound. This latest shipment to Africa, where Millenia has received sales authorizations from 18 different countries, will only bolster the aforementioned and give greater impetus to generate further orders and help alleviate suffering in those regions."
About Millenia Hope
Millenia hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to deliver on medical needs globally and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information please contact:
Mr. Hugo Valente
Tel: (514) 846-5757 or (514) 288-8822
Fax: (514) 935-9758
http://www.milleniahope.com
admin@milleniahope.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Source: Millenia Hope Inc.
A letter from the Chief Executive Officer
Dear Millenia Hope Shareholders,
It is with great pleasure that I take this opportunity to inform you about the exciting activities that have been taking place in the Company and around the malaria world.
Malaria is a major catastrophe for humanity, the scale and impact of the malaria pandemic not only infects 600 million per year and kills 3 million mostly children and pregnant women, it keeps poor people poor. The enormous costs of the morbidity caused in those who survive the infection costs Africa $12 billion US per year in lost working time in industry, care to 400, 000 episodes of severe anemia in pregnancy, 300,000 low-birth-weight babies and 50,000 cases of neurological damage caused by the parasite infection. Children have long periods without school and school teachers because of repeated infections.
Despite the $942 million US has been committed through the Global Fund funding rounds 1, 2 and 3 to support malaria control over the past five years for, medication, insecticides and nets. Approximately 20-30% was spent on the purchase of pharmaceuticals, but the multi-drug resistance in the parasites to the most commonly used drugs has hampered the impact of the money’s placed. Several global foundations have supported research teams to discover vaccines, as yet this has been to no avail. At the G8 meeting in Scotland last week, the 8 richest countries in the world committed funds to finding a solution for poverty Africa, with specific funds devoted to finding prevention and cure for diseases that are destroying the future of the continent, malaria, tuberculosis and HIV/AIDS.
At Millenia Hope we have an important solution to malaria. You, our shareholders, have faithfully supported our mission to bring a cure for malaria to the peoples of the world afflicted with this devastating disease. At times it has been a tough road to travel for all of us, to bring a new class of treatment for a major world disease to a market predominantly in areas supported by aid organization and world authorities. We underestimated the influences that lobbying had on this particular marketplace, and did not have the matching resources to further our cause. The pressures on the global organizations that, until last year, financially supported the more commonly used medications have been enormous. These medications, through the years, have induced drug resistance in malaria parasites world wide, resulting in, as much as, 75% treatment failure rates in many regions and a global increase in malaria cases of 50% since 1998.
The Millenia Hope team has continued its work, focused on bringing the MMH™ Malarex/MMH™18 through clinical trials in Africa. Over 600 patients, both old and young, have taken part in our studies and been cured of their disease. We are saving lives right now!
We have formed Millenia Hope Canada, where we do our research, new product development, manufacturing and market our products; and fought to be recognized by the most influential persons and authorities in the countries where we are working (World Health Organization (WHO), UNICEF, Institute Pasteur). We have formed a scientific advisory board of renowned experts from North America and abroad to support our clinical and new product strategy. We have prepared manuscripts describing our clinical studies shortly to be published in global peer-review journals. We have filed two worldwide patents on our products, acquired another, and have two more patents being drafted. We have obtained authorization to sell in 17 African countries; just recently we received approval in Sierra Leone and Burkina Faso, with applications pending in 10 more. We have filed MMH™ Malarex/MMH™18 with Health Canada to obtain approval in Canada in order to assist in our product recognition by the WHO in Geneva, which will give us access to the global malaria market. We have signed our first letter of intent for sales to a private clinic and distributor in Guinea Conakry who is forming a sales force to be trained in a few weeks. Were are partnering with companies to support our GMP manufacturing and routine quality control, and are exploring the possible cultivation of the peschiera fuchsiaefolia plants for the production of our active ingredients in Canada. We are working on future generations of the products including the prevention of malaria infection and plan to apply to the American Food and Drug Administration (FDA) for an Investigational New Drug (IND) status to run clinical trials in the United States. We have closed an important investment of up to $22 million US, with an influential private investment group that will enable us to implement our business plan.
All of these milestones we have achieved or are in the process of achieving in the coming months. Our new team, headed up by our President Maggie Bywater and Vice President of Research and Development, Soriba Cisse, is continuing to bring the Company to the next level, that of a fully integrated biopharmaceutical company, supplying superior malaria products to counties in extreme need of a cure and prevention for those threatened by the disease. Our corporate development and legal team has been made stronger with the addition new internal and external resources. Their role is building the company profile in the stock markets, and achieving company growth through strategic partnerships and acquisitions of other core biopharmaceutical capabilities.
It is my intension to write to our shareholders on a quarterly basis in the future. I thank you for your loyalty and your belief in Millenia Hope.
Yours sincerely,
Leonard Stella
Chief Executive Officer.
Millenia Hope's Vice-Chairman Resigns Due to Personal Matters
Monday June 20, 7:58 am ET
MONTREAL, June 20 /PRNewswire-FirstCall/ -- Millenia Hope Inc., a Biotech Corporation (OTC Bulletin Board: MLHP - News; Berlin: MLF - News), announced the resignation of its Vice-Chairman of the Board, Dr. Alex Kavic, effective June 15, 2005. Dr. Kavic's personal problems combined with his other employment duties did not allow him to properly fulfill his position as an officer and director of Millenia and the Board of Directors, at a special meeting, asked for and accepted Dr. Kavic's resignation. The Board did not name any replacement for Dr. Kavic, as of this time.
About Millenia Hope
Millenia Hope develops innovative treatments and quality products that will increase the quality of life, provide tools in the fight against devastating diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For more information please contact:
Mr. Hugo Valente
Tel: 514 846-5757 or 514 288-8822
Fax: 514 935-9758
http://www.milleniahope.com
admin@milleniahope.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Millenia Hope Receives Funding in Private Placement
Tuesday May 10, 8:30 am ET
Further Funding Anticipated
MONTREAL, May 10 /PRNewswire-FirstCall/ -- Millenia Hope Inc., a Delaware Bio-pharma corporation (OTC Bulletin Board: MLHP - News; Berlin: MLF - News), today announced the execution of an agreement with an unaffiliated investor, in connection with the sale of shares of restricted common stock of Millenia Hope and the receipt of funding in the amount of $600,000 US. This is the completion of the first stage of an anticipated much larger private placement, being arranged on a "best efforts" basis by Private Consulting Group, Inc. ("PCG"), a registered securities broker dealer headquartered in Portland, Oregon.
Funding from the various investors involved could reach as much as $22,000,000 US, to be raised on a "best efforts" basis by PCG. The receipt of additional funding is subject to certain milestones being reached by Millenia. Various tranches of the common stock are anticipated to be purchased at pre- determined prices.
"This is an important alliance for Millenia Hope, given the investors' excellent affiliations with financial institutions, the worldwide business community and humanitarian organizations around the globe," stated Leonard Stella, CEO of Millenia Hope.
Part of the proceeds of the investment will be used to complete Millenia's current clinical program with MMH Malarex(TM)/MMH 18(TM) in Africa, under protocols monitored by the World Health Organization (WHO), UNICEF, and the Pasteur Institute.
In addition, Millenia Hope intends to further maximize shareholder value by seeking out and acquiring additional products to diversify its product base.
Mr. Stella continued, "There are 300-500 million malaria-infected individuals globally; three (3) million die annually, of which 1 million are children under five (5) years of age. An effective malaria cure is urgently needed. In many regions 70% or more of malaria strains are resistant to existing medications, and the WHO in no longer funding products like chloroquine to which malaria is resistant. MMH Malarex(TM)/MMH 18(TM) cures malaria in those regions where resistant strains are prevalent. This investment will greatly aid Millenia Hope in its primary mission, to save lives in regions afflicted with the devastating effects of this deadly disease."
Stella concluded, "This funding will enhance Millenia's goal to be a global force in the treatment of malaria."
About Millenia Hope
Millenia Hope develops innovative treatments and quality products that will increase the quality of life, provide tools in the fight against devastating diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For more information, please contact:
Mr. Hugo Valente
Tel: 514 846-5757 0r 514 288-8822
Fax: 514 935-9758
http://www.milleniahope.com
admin@milleniahope.com
Millenia Hope Strengthens Management Team
Wednesday April 27, 2:15 pm ET
MONTREAL, April 27 /PRNewswire-FirstCall/ -- Millenia Hope Inc., a Biotech Corporation (OTC Bulletin Board: MLHP - News; Berlin: MLF - News), solidified its management team by adding several key people.
Millenia Hope recently announced the appointment of Dr. Soriba Cisse as Vice President R&D. Dr. Cisse has a medical background from the University of Abidjan, Ivory Coast, and received his BSc. and MSc. in Cell Biology at the University of Quebec at Montreal, and Ph.D. in Neuroscience, at the University of Montreal, 1980-1994. "Since joining the Company I have been extremely impressed by the quality of the science," said Dr. Cisse. "I am working on five dissertations to be published in world class journals with my colleagues running our ongoing studies in the field."
Dr. Cisse has many personal achievements, including participating in an award-winning team on a multidisciplinary approach to the genetics and epidemiology of Alzheimer's disease. His work led to fundamental discoveries in the aging human brain. He also did research at the laboratory of Nobel Prize winner James Watson at Cold Spring Harbor and at Case Western in Cleveland with Alzheimer expert George Perry, followed by a post-doc at the Jewish General Hospital in Montreal. For eight years Dr. Cisse was scientific advisor to the AIDS program of FONDIS and a special advisor to Minister of Health in Guinea Conakry. He has held positions as Director of Quality Control and later as Vice President R&D in BioMedco Canada Inc., developing immunodiagnostic kits.
Carole Robert has joined as Vice President Government Affairs & Sales Development. Robert has a strong background in international trade in emerging markets, establishing distribution networks in Eastern Europe. Robert has received several national prizes for her achievements and was a member of the Board of Directors and Executive Committee, Montreal International, 1997-2002, and Chairperson of the Board, the World Trade Centre Montreal, 1996-2000. She was also Canadian delegate at the Muenster Conference, preparatory meeting for G-7 (1996-1998), and a Member of the Intergovernmental Economical Commission, Canada - Russia (1994-1999).
"We are very pleased to have a person of Carole's caliber dealing with our Government Affairs," said Margaret Bywater, President of Millenia. "It is very tricky to pilot international sales in developing countries through to completion. Carole has a wide experience in making sure the sales happen!"
Joseph Daniele has joined the Millenia Hope team as Chief Legal Advisor. Daniele received his BA at McGill University in Montreal and his law degree from the University of Sherbrooke. He has been practicing law since 1987 at Bissonet, Mecandante, Daniele, making partner in 1989. In recent years he has specialized in financial transactions. An investor in Millenia Hope, Daniele has followed the Company for years and now joins the team to assist Millenia on a full-time basis.
"With the recruitment of Soriba, Joseph and Carole, Dr. Bywater is putting a team in place to bring the company to the next level," commented Leonard Stella, CEO. "I look forward to reporting our imminent successes to our investors."
Mr. Stella continued, "We are also strengthening our financial team with the appointment of Mario Dumais as head of our Investor Relations. He is a successful Montreal businessman who has a wealth of corporate experience, and is phenomenal at maintaining relationships with his clients." Mr. Dumais has, over the years, established and maintained many high-level relationships in the international business world, financial institutions and the diplomatic corps.
About Millenia Hope
Millenia Hope develops innovative treatments and quality products that will increase the quality of life, provide tools in the fight against devastating diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For more information, please contact:
Mr. Hugo Valente
Tel: 514 846-5757 or 514 288-8822
Fax: 514 935-9758 or 514 333-6460
http://www.milleniahope.com
admin@milleniahope.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Millenia Hope Opens Subsidiary in Asia
Friday April 15, 11:37 am ET
MONTREAL, April 15 /PRNewswire-FirstCall/ -- Millenia Hope Inc., a Biotech Corporation (OTC Bulletin Board: MLHP - News; Berlin: MLF - News), announced today the addition of Mr. Jacky Quan to the Board of Directors. Quan will also be taking the founding position of President of Millenia Hope, Hong Kong. Millenia Hope will strategically open a wholly owned subsidiary in Hong Kong as a stepping stone for the company to enter the Asian and Indonesian malaria markets. Millenia will be managing the sales in the Pacific Rim, China, Indonesia and SE Asia from Hong Kong.
Born in China and educated in Vietnam and China, Quan is fluent in several SE Asian languages, as well as Mandarin and Cantonese. He is a highly successful businessman in his own right, with an influential global network of financiers and business associates.
"Jacky brings a background in and knowledge of the Asian business culture which is invaluable to Millenia Hope. We have a valuable resource in Jacky, especially now when we are opening discussions in the Asian markets," said Margaret Bywater, President of Millenia Hope. "We are in the process of revising our business plan to cover not only our projected sales in Africa, but we are also looking to Asia for longer-term revenues. Mr. Quan will be instrumental in the direct contact with Millenia Hope distributors in these markets."
"We are aware of the biotech manufacturing possibilities in Asia and Indonesia and are open to partnering to further develop our manufacturing process," said Leo Stella, CEO of Millenia Hope. "With our management expertise in biotechnology and genetics, we are equipped to select the most efficient and cost-effective approach to meet global needs."
About Millenia Hope
Millenia Hope develops innovative treatments and quality products that will increase the quality of life, provide tools in the fight against devastating diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For more information, please contact:
Mr. Hugo Valente
Tel: 514 846-5757 or 514 288-8822
Fax: 514 935-9758
http://www.milleniahope.com
hugo@milleniahope.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Source: Millenia Hope Inc.
Millenia Hope Appoints President
Thursday April 14, 2:27 pm ET
- Biotech Industry Veteran to Run Day to Day Operations
MONTREAL, April 14 /PRNewswire-FirstCall/ -- Millenia Hope Inc., a Biotech Corporation (OTC Bulletin Board: MLHP - News; Berlin-MLF), announced today that Margaret (Maggie) Bywater has joined the company as President. Bywater started her scientific career in the field of genetics of disease in the 1970s. She received her degree from the Medical Faculty at the University of Uppsala Sweden (1975), where she did a masters in Molecular Pathology. She was associated with the university for more than a decade.
Her business career started in biotech/healthcare at Pharmacia in Sweden, where she helped develop and market a diagnostic system to identify genetic markers in breast cancer predicting response to therapy. During the past two decades she held positions, including clinical operations and technology transfer, in both start-ups and large corporations in Europe and US. She was corporate Staff Vice President-Pharmaceutical Business Development at The Perkin Elmer Corporation in the US, a $1.3 billion biotech, where she was involved in corporate strategy for mergers and acquisitions. As General Manager of the newly acquired PE GenScope, in California, she became familiar with executive sales of high ticket transactions with pharma. In Canada she was president of two early stage drug discovery companies.
Maggie comes to Millenia Hope from H3 Pharma, Montreal, as Vice President of Business Development & Licensing. She headed new medications acquisitions, managed due diligence, and negotiated and structured deals, in-licensing for clinical development and out-licensing for distribution, marketing and sales. Maggie has an extensive clinical network, in academia and healthcare.
Leonard Stella, CEO Millenia Hope, stated, "Maggie has a strong background in biotech business transactions, operations and intellectual property. I am delighted to welcome Maggie in the President's role at Millenia, at this time in our company's development." He continued, "Millenia Hope has the right to sell MMH Malarex/MMH-18 in 16 countries and is involved in ongoing discussions with distribution candidates in malaria markets. Maggie will lead the commercialization of our product and manage the R&D team in the clinical studies underway in four African countries."
About Millenia Hope:
Millenia Hope develops innovative treatments and quality products that will increase the quality of life, provide tools in the fight against devastating diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.
Safe Harbor Statement:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
This release was issued through Major Newswire (http://www.majornewswire.com).
Millenia Hope to Sponsor Anti-Malarial Study With Knox Van Dyke
Wednesday March 2, 8:00 am ET
MONTREAL, March 2 /PRNewswire-FirstCall/ -- Millenia Hope Inc., a Biotech Corporation (OTC Bulletin Board: MLHP - News; Berlin: MLF - News), announced that it is finalizing the sponsorship of a new anti-malarial study to start this year. This will be a "first in man" study, supervised by world renowned malaria expert, Dr. Knox Van Dyke, in the US, based on Millenia Hope's newly acquired therapeutic molecule, Tranex18. This study will focus on the development of this novel molecule in the treatment of malaria and other diseases, with specific emphasis on the drug-resistance mechanism in chloroquine resistant Plasmodium falciparum.
Millenia's ongoing research and development efforts includes successfully concluded treatment of the primary disease in infected individuals in the Republic of Central Africa (RCA) and Cameroon, with MMH18 Malarex, as well as an ongoing large scale pediatric trial, monitored by the WHO in RCA. This announcement illustrates the Company's two-pronged approach to the fight against this devastating disease. Apart from the direct approach to treatment, an additional clinical strategy is to administer Tranex18 in association with standard drugs, like chloroquine, against resistant strains.
Furthermore, Millenia Hope takes great pleasure in welcoming Dr. Soriba Cisse as Vice-President in charge of Research and Development; Dr. Cisse and Dr. Jean Pierre Willem, will be joining the Scientific Advisory Committee. Dr. Cisse, a neurobiologist trained at McGill University and Universite de Montreal, will head Millenia's product development. Dr. Willem, is a highly honored humanitarian holding degrees in several medical specialties, and is an expert in naturally derived medicinals. He has been associated with malaria stricken regions for more than 40 years.
"Millenia Hope has been significantly raising its scientific profile, both in its clinical approach and its personnel," said Leonard Stella, CEO of Millenia. "We are determined to become a leader in the fight against malaria. We expect the consequent scientific benefits to generate a healthy return for our shareholders, as well."
Dr. Meir Sacks, Chief of Pharmacology, added, "Strengthening the science platform on which we build our products and broadening the scientific knowledge base of our company can only lead to greater achievements."
About Millenia Hope:
Millenia Hope develops innovative treatments and quality products that will increase the quality of life, provide tools in the fight against devastating diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.
Safe Harbor Statement:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
This release was issued through Major Newswire (http://www.majornewswire.com).
Source: Millenia Hope Inc.
MILLENIA HOPE INITIATES W.H.O. MONITORED PEDIATRIC ANTI-MALARIA TRIAL WITH MMH8™ MALAREX
MONTREAL, Canada (Feb 22, 2005)
Millenia Hope Inc., a Biotech Corporation (MLHP-OTCBB) (MLF- Berlin), announced that it has initiated a second Company sponsored trial in the Republic of Central Africa (RCA).
The 360 patient trial, is under the watchful eye of the World Health Organization, UNICEF and the Pasteur Institute, France. This trial follows the Company’s recent success with three efficacy trials; on 33 adults using MMH18™ adult formulation and in 30 children (12-60 months) withMMH 8™, the pediatric formulation of MMH 18™ in RCA; and with Camoquin 200 as a comparator in 52 adults in Cameroon.
The new Millenia Hope trial is an extended study in the pediatric patient group, previously studied (12-60 months), with non-complicated malaria, (children with no signs of malnutrition and/or other diseases including HIV and Hepatitis). It will be carried out in three major cities in RCA.
A five-day treatment of MMH™ reduces the fever, in the majority of patients within three to four days and significantly decreases the parasite density per µl of blood, (from as high as 50 000 per µl to > 200) in five days. In all patients the parasite density was decreased to zero within seven days, and the disease-associated anemia improved significantly during the 14-day follow-up period.
Leonard Stella, CEO at Millenia Hope reports, “MMH Malarex™ has a major impact on drug-resistant strains of malaria when administered to patients in areas where these are the prevalent strains.” He continued, “We are ecstatic that the WHO, UNICEF and the Pasteur Institute are monitoring this study and have approved the protocol. This is a major step forward for the Company to interest these organizations in our products.”
“Millenia Hope has been engaged in the fight against malaria for more than 8 years. We have permission to sell our products in 16 countries, with three more to come,” says Hugo Valente, CFO “Our aim this year is to sell 300,000 treatments in two major markets”. Malaria claims nearly 3 million lives annually and its global market is estimated at $10 billion US.
MONTREAL, Canada (Feb 22, 2005)
Millenia Hope Inc., a Biotech Corporation (MLHP-OTCBB) (MLF- Berlin), announced that it has initiated a second Company sponsored trial in the Republic of Central Africa (RCA).
The 360 patient trial, is under the watchful eye of the World Health Organization, UNICEF and the Pasteur Institute, France. This trial follows the Company’s recent success with three efficacy trials; on 33 adults using MMH18™ adult formulation and in 30 children (12-60 months) with MMH 8™, the pediatric formulation of MMH 18™ in RCA; and with Camoquin 200 as a comparator in 52 adults in Cameroon.
The new Millenia Hope trial is an extended study in the pediatric patient group, previously studied (12-60 months), with non-complicated malaria, (children with no signs of malnutrition and/or other diseases including HIV and Hepatitis). It will be carried out in three major cities in RCA.
A five-day treatment of MMH™ reduces the fever, in the majority of patients within three to four days and significantly decreases the parasite density per µl of blood, (from as high as 50 000 per µl to > 200) in five days. In all patients the parasite density was decreased to zero within seven days, and the disease-associated anemia improved significantly during the 14-day follow-up period.
Leonard Stella, CEO at Millenia Hope reports, “MMH Malarex™ has a major impact on drug-resistant strains of malaria when administered to patients in areas where these are the prevalent strains.” He continued, “We are ecstatic that the WHO, UNICEF and the Pasteur Institute are monitoring this study and have approved the protocol. This is a major step forward for the Company to interest these organizations in our products.”
“Millenia Hope has been engaged in the fight against malaria for more than 8 years. We have permission to sell our products in 16 countries, with three more to come,” says Hugo Valente, CFO “Our aim this year is to sell 300,000 treatments in two major markets”. Malaria claims nearly 3 million lives annually and its global market is estimated at $10 billion US.
MILLENIA HOPE BUYS RIGHTS TO PHASE III CANCER AND ANTI-MALARIA PRODUCT FROM DR. KNOX VAN DYKE
MONTREAL, Canada (Feb 11, 2005)
Millenia Hope Inc., a Biotech Corporation (MLHP-OTCBB) (Berlin Stock Exchange-MLF), announced today that it has acquired the global patent rights to develop, manufacture and distribute, for all indications, Tetrandrine from inventor Dr. Knox Van Dyke, an internationally renowned researcher from the University of West Virginia.
Millenia Hope is focused on the development of anti-malaria products and is actively engaged in the fight against this disease that claims nearly 3 million lives every year. In 2002 the global market for malaria was estimated at approximately $10 billion US. Tetrandrine aids the treatment of drug-resistant strains of malaria when administered together with standard therapies. The Company’s interest in Tetrandrine was recently peaked by the fact that Dr Van Dyke is scheduled to present to the Medicines for Malaria Venture (MMV) in Geneva, Switzerland. The MMV is a non-profit organization, charged with the mission to identify and fund new anti-malarial medications. Furthermore, Tetrandrine will be tested at the Walter Reed Medical Center, in Washington, D.C., for its anti-malarial properties.
“Tetrandrine adds to our pipeline of products targeting malaria, which include MMH18 /MMHMalarex and Malarex, currently in further clinical studies in Africa”, said Leonard Stella CEO of Millenia Hope Inc. He continued, “Our collaboration with Dr. Van Dyke, who is a globally recognized authority on malaria, pharmacology, toxicology and several other disciplines, will give great credence and credibility to the Company’s efforts in the field, and yield broad scientific and commercial opportunities now and in the future.”
Tetrandrine also demonstrates efficacy in colorectal cancer patients in the clinical setting and Phase III FDA trials, in this indication, are ongoing in the United States.
“It’s a pleasure for me to share this opportunity with Millenia Hope Inc. Finally, a company whose very essence is its dedication to discovering anti-malarial solutions, by thinking outside the box” said Dr. Knox Van Dyke.
Dr. Myer Sacks, Chief of Pharmacology at Millenia Hope, declared that, “the business world should take an active interest in the anti malarial cause by sponsoring studies for small pharmaceutical companies”.
Millenia Hope Inc. Announces the Creation of the Millenia Hope Foundation (Europe)
MONTREAL, Aug. 31 /PRNewswire-FirstCall
Millenia Hope Inc., a Biotech Corporation (OTC Bulletin Board: MLHP - News; Berlin Stock Exchange: MLF - News), proudly announces that it is in the process of creating THE MILLENIA HOPE FOUNDATION (Europe), a private foundation, through the legal firm of Osborne Clarke.
Its mission is to help humanity in its hour of need, to assist children and adults who have contracted tropical infectious diseases, in particular Malaria.
The Foundation is non-political, relying solely on moral conscience and bolstered by generous monetary contributions to help all, without discrimination of any sort, in their moment of need.
The Foundation's goal is to locate and harness the resources necessary to attain its raison d'etre.
Millenia Hope will be soliciting prominent individuals to participate as ambassadors for this cause in the near future
Millenia Hope Inc. also announces the registration of Millenia Hope Pharmaceuticals U.K. This entity will help contribute to Millenia Hope's goal of having an international presence and allow Millenia to interconnect with other scientific and humanitarian programs that have a similar objective.
About Millenia Hope:
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to deliver on medical needs globally and to bring hope through healthcare solutions.
Safe Harbor Statement:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
This release was issued through Major Newswire (http://www.majornewswire.com).
DR. ALEXANDER KAVIC APPOINTED VICE-CHAIRMAN OF MILLENIA HOPE
MONTREAL, Canada (August 3, 2004) – Millenia Hope Inc., a Biotech Corporation (MLHP-OTC:BB) (Berlin Stock Exchange – MLF), is pleased to announce the acceptance of the position of Vice-Chairman of the Board of Directors of Millenia Hope., previously held by Dr. David Mulder, by Dr. Alexander Kavic of Pittsburgh, Pennsylvania.
Dr. Kavic received his M.D. in 1968 and his Board certification in Emergency Medicine in 1987. Dr. Kavic's list of professional appointments, medical consultantships and licensures and volunteer placements are too numerous to list.
However, amongst his accomplishments, over the previous 4 decades, are the Chairmanship of the Aliquippa Community Hospital and its sister foundation and being elected as a member of the Board of Trustees and Chairman of the Department of Emergency Medicine of Monsour Medical Center.
"As Millenia moves forward, in its inexorable effort to help eradicate the scourge of malaria, we are honored and look to the future with great anticipation to have a notable physician of Dr. Kavic's stature join our battle. With Dr. Kavic's added leadership Millenia is another step closer to achieving our ultimate goal," stated Leonard Stella, CEO of Millenia Hope.
About Millenia Hope:
Millenia hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to deliver on medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as “forward-looking statements”. Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Leonard Stella, CEO Millenia Hope Inc.
Tel: (514) 846-5757
E-mail: leostella@milleniahope.com
Web site: www.milleniahope.com
MILLENIA HOPE SHAREHOLDERS AUTHORIZE ENHANCED CAPITAL STRUCTURE AND BOARD OF DIRECTORS
MONTREAL, Canada (July 27, 2004) – Millenia Hope Inc., a Biotech Corporation (MLHP-OTC:BB) (Berlin Stock Exchange – MLF), is proud to announce the results of its July 15, 2004 annual shareholders meeting held in Newark, Delaware. The shareholders approved an amendment to increase the authorized common shares from 70 million to 180 million, by a positive vote of 51.19% of the shares outstanding. The shareholders approved an amendment to authorize the issue of 50 million preferred shares by a positive vote of 51.28 % of the shares outstanding. The plurality of votes, by the voting shareholders, elected the following as directors of Millenia Hope: Yehuda Kops, Raymond Roy, Leonard Stella and Hugo Valente.
"We would like to thank our shareholders who took the time and effort to exercise their voting rights. The positive mandate given to Millenia Hope and its elected directors will give us renewed strength and vigor in our ongoing battle to eliminate malaria and position Millenia in the forefront of that battle", declared Leonard Stella, CEO of Millenia Hope.
Millenia Hope is also pleased to announce that, following the reception of 11 selling authorizations for the African continent and 1 for the Caribbean nation of the Dominican Republic, we have received authorizations from West Africa for the Democratic Republic of Congo, Mali, Mauritania and the East African nation of Ghana.
The company also reported excellent results for its new product, BEBE MMH MALAREX™ specifically designed for young children under 5 years of age, performed by Dr. Wilfrid Nambei, in the Republic of Central Africa. The tests yielded very positive results and the complete study will be announced at a later date in a scientific document destined for peer-reviewed publication.
The company is also embarking on a series of tests, to be done in the near future, utilizing a broader base of 2000 subjects. The positive results to be garnered from the aforementioned, in conjunction with our other previously conducted positive testing regimens will help us reach our goal of receiving official recognition , for MMH MALAREX™, from the World Health Organization.
Malaria, one of the world's most insidious diseases, affects over 500 million people annually in all regions of the world; Africa, the Indian subcontinent, South East Asia and Central and South America.
About Millenia Hope:
Millenia hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to deliver on medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as “forward-looking statements”. Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Leonard Stella, CEO Millenia Hope Inc.
Tel: (514) 846-5757
E-mail: leostella@milleniahope.com
Web site: www.milleniahope.com
Millenia Hope Appoints Dr. Wilfred Sylvain Nambei as a Member of Its Scientific Committee
June 01, 2004 08:02:00 AM ET
Clinical Tests Performed With MMH MALAREX(TM) and Its New BEBE MMH MALAREX(TM) for Young Children are Very Positive
MONTREAL, June 1 /PRNewswire-FirstCall/ -- Millenia Hope Inc. a Biotech Corporation (OTC Bulletin Board: MLHP) (BERLIN: MLF) is pleased to announce that Dr. Wilfred Sylvain Nambei has joined its Scientific Committee after a highly successful trial of Millenia Hope's anti-malarial agent for young children, BEBE MMH MALAREX(TM). The official results of this study will be released in the near future, as soon as they become available. A previously run trial of MMH MALAREX(TM), by Dr, Nambei in Bangui, the Central African Republic, also yielded excellent clinical results.
Dr. Nambei received his Pharmacology degree in 1996, at the Medical and Pharmacology Faculty of the University Cheikh Anta Diop de Dakar, Senegal, and his PhD in Pharmacology, with great Honors, at the same University in 1997. Dr. Nambei received his degree in General Immunology and Immunophysics in infectious diseases from the Institut Pasteur, Paris, France, in 1999, the year in which he also completed a D.E.A. in Chemistry and Biochemistry, in natural products, at the faculty of Natural Sciences and Technology at the UCAD, Senegal.
Dr. Nambei has been the Chief of Pharmacology and Medicine at l'Hopital Communautaire de Bangui, Central African Republic, since 2002 and the chief of Parasitology and Microbiology at Cerphameta, University of Bangui since 2000. From 1995 onward, he has worked at a variety of posts, at The Institut Pasteur of Dakar, and at other recognized medical institutions. Dr. Nambei has published many scholarly works regarding his much recognized research on Plasmodium Falciparum (malaria) parasites and their effects on blood cells.
"We are pleased to have such a renowned scientist join our Scientific Committee," said Leonard Stella, CEO of Millenia Hope. "This again shows that our anti-malarial product, MMH MALAREX(TM), is being well received in countries in which malaria is endemic."
About Millenia Hope:
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements". Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
Millenia Hope Receives Dominican Republic Selling Authorization
MONTREAL, Feb. 18 /PRNewswire-FirstCall/ -- Millenia Hope Inc., a Biotech Corporation (OTC Bulletin Board: MLHP - News; Berlin: MLF - News), is pleased to announce that, following the reception of 11 selling authorizations for the African continent, the Republic of Guinea (Conakry), Republic of Congo (Brazzaville), Republic of Togo, Burundi, the Central African Republic, Benin, Gabon, Chad, Senegal, Niger and Cameroon, we have received our first selling authorization for the Western Hemisphere, from the Caribbean nation of the Dominican Republic, for our anti-malarial product, Malarex(TM).
Malaria, one of the world's most insidious diseases, affects over 500 million people annually in all regions of the world, Africa, the Indian subcontinent, South East Asia and Central and South America.
"Millenia Hope is branching out from its African distribution program, globally, the most malarial afflicted region, to include the other malaria affected areas of the world. It is our hope and goal to fight and eventually eradicate the scourge of malaria worldwide," declared Mr. Leonard Stella, CEO of Millenia Hope.
About Millenia Hope:
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Leonard Stella
Chief Operating Officer
(514) 846-5757
E-mail: leostella@milleniahope.com
Web: www.milleniahope.com
Jacky Quan Joins Millenia Hope
MONTREAL, Feb. 12, 2004 (PRIMEZONE) -- Millenia Hope Inc., a Biotech Corporation (OTC BB:MLHP.OB - News) (Berlin Stock Exchange:MLF) today announced that Jacky Quan has joined the company as Vice-President - Sales for Asia and South America.
Mr. Quan, an international businessman, active in the capital markets for funding of start up companies, has extensive ties and relationships in the Asian marketplace, specifically with the Vietnamese and Chinese communities and the Hispanic markets of the Caribbean and South America.
Mr. Leonard Stella, CEO of Millenia Hope commented, ``We are pleased to have Mr. Quan joining our corporation for his dynamism and his many contacts in Asia and South America. We are at the stage of commercialization of our anti-malarial product, MMH MALAREX(TM), and Mr. Quan's business acumen and relationships will aid in elevating Millenia to greater heights.''
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. The company's people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as ``forward-looking statements''. Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Leonard Stella
Chief Operating Officer
(514) 846-5757
E-mail: leostella@milleniahope.com
Web: www.milleniahope.com
DR. THOMAS P TREICHLER JOINS THE BOARD OF MILLENIA HOPE
Thursday November 13, 5:40 pm ET
MONTREAL, Nov. 13, 2003 (PRIMEZONE) -- Millenia Hope Inc., a biotech company traded on the OTC Bulletin Board (OTC BB:MLHP.OB - News) (Berlin:MLF), is pleased to announce the addition of Dr. Thomas P. Treichler to its Board of Directors.
Dr. Treichler, holder of a Doctorate in Japanese Law from Zurich University, was educated in Switzerland and Japan. His many years of wide ranging experience in the United States, Asia, Australia and Europe have encompassed corporate finance, corporate governance, and investment banking and venture capital investment.
His career began in 1969 with the Union Bank of Switzerland in Tokyo and Zurich and in London with J. Henry Schroder Wagg. In 1976 he co-founded Fidenas Corporation, a New York based investment banking and finance firm. Dr. Treichler is also the founder and chief executive officer of Orient Financial Corporation, a San Francisco based investment banking and corporate advisory firm, whose clientele includes emerging companies in the biomedical and technology fields.
``Dr. Treichler will be a great asset to Millenia Hope and his vast experience in finance will be vital to the firm,'' said Mr. Leonardo Stella, CEO of Millenia Hope.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as ``forward-looking statements''. Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Leonard Stella
Chief Operating Officer
(514) 846-5757
E-mail: leostella@milleniahope.com
Web: www.milleniahope.com
Form 10-Q/A for MILLENIA HOPE INC
25-Jul-2003
Quarterly Report
Plan of Operation.
The following discussion should be read in conjunction with the financial statements and related notes which are included elsewhere in this prospectus. Statements made below which are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties including, but not limited to, general economic conditions and our ability to market our product.
The business objectives of Millenia are twofold. First and foremost is to establish MALAREX as an accepted control agent for the treatment and prevention of malaria throughout the world. Not only do we believe that MALAREX is an effective anti-malarial drug, it will also be made available at prices that are adapted to the realities of the third world market. The availability and pricing of MALAREX, we believe, will ensure its acceptability and use in the fight against malaria. To this end the company is involved with ongoing clinical trials of MALAREX. As of February 28, 2003, Millenia Hope had received 8 sales authorizations from West African nations, Congo (Brazzaville) and Guinea (Conakry), Togo, Burundi, Central African Republic, Benin, Gabon and Chad. We are awaiting sales authorizations from several other West African nations. Based on managements best estimates, Millenia hopes to sell up to 1 million treatments of Malarex or $7 million worth, by the end of fiscal 2003.
Millenia has adopted an extremely conservative sales forecast. In the face of anti-malarial drug resistance, the need for more effective treatments will continue to intensify. Once a network of local manufacturers and distributors capable of producing and supplying MALAREX are in place, the demand for MALAREX should increase commensurately.
It is estimated the demand for MALAREX will increase as it becomes one of the accepted choices in the fight against malaria. Millenia has chosen to remain conservative and has established a goal of capturing 2% ($200 million) of the marketplace in five years. According to the company's internal estimates, based upon it's knowledge of the industry, attaining this sales level will ensure the viability and profitability of the Company for its shareholders. No assurance can be given that the Company will meet its sales goals.
Secondly, Millenia is committed to ongoing research and development to expand the efficacy of MALAREX and its derivatives in fighting infectious diseases. As the company has not yet made any significant sales of its product, it is difficult for management to evaluate the growth curve of Product sales. However, given the market size and the need for viable and effective drugs, the Company believes that it will not have a problem generating sales thereby creating positive cash flow once further authorizations have been obtained.
On May 29, 2000, the company acquired thirty five million seven hundred thousand (35,700,000) shares of SWORD COMP-SOFT CORP., this being 76.5% of SWORD's issued capital, at a cost of five million (5,000,000) common shares, and five million warrants (5,000,000), entitling the registered holder thereof to purchase at any time from that date for a period of three (3) years, one share of common stock at a price of two dollars ($2).
SWORD COMP-SOFT CORP. was an (ASP) Application Service Provider incorporated in November 1998 specializing in the E-Healthcare sector.
Application services, a rapidly growing segment of the Internet economy, are those that focus on a single topic or issue in a conversational manner. Essentially, the subscribers use application programs to create, store and transact medical data on the application server, for example, the interactive on-line health service will record similar data to that usually given to a primary health care worker, such as a doctor or a nurse,, and create an overall profile of individual health needs. Each application will relate to a specific disease, drug, or part of the human anatomy on a pay per use basis ( although this fee may be sponsored).
On March 5, 2003, Millenia divested its entire holding in Sword Comp-Soft, this being 30.7 million common shares. The aforementioned shares were tendered back to Sword Comp-Soft. In exchange for said 30.7 million shares, Sword Comp-Soft paid Millenia Hope $700,000 U.S., due within 12 months from the date of its signing of the agreement and gave Millenia its Medico Center site, Medico Research, any other related Medico
ASP work and all the attended backup documentation, computer line code etc., all is per the agreement signed on March 5, 2003.
The acquisition of Sword`s medical ASP's and Medico Records accessible on the Internet, where 45% of all inquiries are health related, is highly beneficial, as Millenia's scientific advisory committee, comprised of M.D.s and P.H.D.s with a wide range of expertise, will lend valuable assistance as we strive to bring to the market medical ASPs. Further, their breadth of knowledge and varied specializations should help to generate ideas and data to aid in the production of other medical ASP's.
On October 10, 2001 Millenia Hope and Cibecol Industrial Farmaceutica Ltda. Signed a purchase agreement via which Millenia will acquire 68% of the assets of Cibecol for $500,000 in cash, 7 million shares of Millenia Hope common shares and 1 million common shares of Sword Comp-Soft., a subsidiary of Millenia Hope, that are owned by Millenia.
Cibecol, incorporated and headquartered in Brazil, operates a 20,000 square foot manufacturing facility and also owns 82 hectares of arable land, located, Porto Allegre, Brazil. Millenia will use the Brazilian facility for the production of Malarex.
Cibecol, which has been in business for over 20 years, operates one of the largest phyto-pharmaceutical plants in southern Brazil. In addition to producing voacamine, the active agent in Malarex, Cibecol would continue to produce its own group of 61 natural medicines that are currently being Marketed in Brazil. This acquisition would be a key step forward toward Millenia's goal of becoming a vertically integrated producer and distributor of Malarex.
Furthermore, Millenia, under the leadership of Dr. David Mulder, Millenia's Vice Chairman, and Dr. Rene Morel, a member of our scientific committee, expect to introduce a new concept which we call 02-IV, oxygenation of intravenous solutions. Intravenous solution recipients will now be able to derive a positive boost from the extra dose of oxygen delivered directly to their blood stream.
The North American intravenous solution market, per estimates of Frost & Sullivan, is approximately $1.3 billion and the rest of the international market is about an additional $1.5 billion.
On May 31, 2001, Millenia Hope and Liquid Asset Corp. signed a purchase agreement, the terms of which give Millenia the exclusive worldwide rights to oxygenate intravenous solutions until September 1, 2005 with an option to purchase these same rights for a further 5 year period. The purchase price for these rights to September 1, 2005 is $500,000 in cash, 6 million Millenia Hope common shares and 2 million non-registered common shares of Sword Comp-Soft Corp. that are owned by Millenia.
Millenia has come to an agreement to utilize the services of Ropack, an FDA approved, HACCP and cGMP Compliant and ISO 9002 certified corporation, to perform quality control and all encapsulating of MALAREX(TM), confirming to U.S. and Canadian manufacturing standards. Assure the highest possible level of quality via product analysis and homogeneity testing for MALAREX(TM). This manufacturing facility, fully adhering to the highest quality standards of good manufacturing procedures, gives credence and assurance of the purity and safety of our final product. Ropack is accredited by both the U.S. and Canadian armies.
Liquidity and cash flow needs of the company
From December 1st, 2002 to May 31, 2003 the company and its subsidiary until March 5, 2003, incurred operating and interest expenses in the amount of $224,416 while recording net cash revenues of $47,630. from June 1st, 2003 to November 30th, 2003, the fiscal year end, the company anticipates that its net cash flow needs, will be $250,000 primarily to cover day today operating expenses. These funds will be covered by revenue received and any shortfalls will be met by the officers and certain shareholders as previously outlined.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Leonard Stella
Chief Operating Officer
(514) 846-5757
E-mail: leostella@milleniahope.com
Web: www.milleniahope.com
Form 10-Q/A for MILLENIA HOPE INC
25-Jul-2003
Quarterly Report
Plan of Operation.
The following discussion should be read in conjunction with the financial statements and related notes which are included elsewhere in this prospectus. Statements made below which are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties including, but not limited to, general economic conditions and our ability to market our product.
The business objectives of Millenia are twofold. First and foremost is to establish MALAREX as an accepted control agent for the treatment and prevention of malaria throughout the world. Not only do we believe that MALAREX is an effective anti-malarial drug, it will also be made available at prices that are adapted to the realities of the third world market. The availability and pricing of MALAREX, we believe, will ensure its acceptability and use in the fight against malaria. To this end the company is involved with ongoing clinical trials of MALAREX. As of February 28, 2003, Millenia Hope had received 8 sales authorizations from West African nations, Congo (Brazzaville) and Guinea (Conakry), Togo, Burundi, Central African Republic, Benin, Gabon and Chad. We are awaiting sales authorizations from several other West African nations. Based on managements best estimates, Millenia hopes to sell up to 1 million treatments of Malarex or $7 million worth, by the end of fiscal 2003.
Millenia has adopted an extremely conservative sales forecast. In the face of anti-malarial drug resistance, the need for more effective treatments will continue to intensify. Once a network of local manufacturers and distributors capable of producing and supplying MALAREX are in place, the demand for MALAREX should increase commensurately.
It is estimated the demand for MALAREX will increase as it becomes one of the accepted choices in the fight against malaria. Millenia has chosen to remain conservative and has established a goal of capturing 2% ($200 million) of the marketplace in five years. According to the company's internal estimates, based upon it's knowledge of the industry, attaining this sales level will ensure the viability and profitability of the Company for its shareholders. No assurance can be given that the Company will meet its sales goals.
Secondly, Millenia is committed to ongoing research and development to expand the efficacy of MALAREX and its derivatives in fighting infectious diseases. As the company has not yet made any significant sales of its product, it is difficult for management to evaluate the growth curve of Product sales. However, given the market size and the need for viable and effective drugs, the Company believes that it will not have a problem generating sales thereby creating positive cash flow once further authorizations have been obtained.
On May 29, 2000, the company acquired thirty five million seven hundred thousand (35,700,000) shares of SWORD COMP-SOFT CORP., this being 76.5% of SWORD's issued capital, at a cost of five million (5,000,000) common shares, and five million warrants (5,000,000), entitling the registered holder thereof to purchase at any time from that date for a period of three (3) years, one share of common stock at a price of two dollars ($2).
SWORD COMP-SOFT CORP. was an (ASP) Application Service Provider incorporated in November 1998 specializing in the E-Healthcare sector.
Application services, a rapidly growing segment of the Internet economy, are those that focus on a single topic or issue in a conversational manner. Essentially, the subscribers use application programs to create, store and transact medical data on the application server, for example, the interactive on-line health service will record similar data to that usually given to a primary health care worker, such as a doctor or a nurse,, and create an overall profile of individual health needs. Each application will relate to a specific disease, drug, or part of the human anatomy on a pay per use basis ( although this fee may be sponsored).
On March 5, 2003, Millenia divested its entire holding in Sword Comp-Soft, this being 30.7 million common shares. The aforementioned shares were tendered back to Sword Comp-Soft. In exchange for said 30.7 million shares, Sword Comp-Soft paid Millenia Hope $700,000 U.S., due within 12 months from the date of its signing of the agreement and gave Millenia its Medico Center site, Medico Research, any other related Medico
ASP work and all the attended backup documentation, computer line code etc., all is per the agreement signed on March 5, 2003.
The acquisition of Sword`s medical ASP's and Medico Records accessible on the Internet, where 45% of all inquiries are health related, is highly beneficial, as Millenia's scientific advisory committee, comprised of M.D.s and P.H.D.s with a wide range of expertise, will lend valuable assistance as we strive to bring to the market medical ASPs. Further, their breadth of knowledge and varied specializations should help to generate ideas and data to aid in the production of other medical ASP's.
On October 10, 2001 Millenia Hope and Cibecol Industrial Farmaceutica Ltda. Signed a purchase agreement via which Millenia will acquire 68% of the assets of Cibecol for $500,000 in cash, 7 million shares of Millenia Hope common shares and 1 million common shares of Sword Comp-Soft., a subsidiary of Millenia Hope, that are owned by Millenia.
Cibecol, incorporated and headquartered in Brazil, operates a 20,000 square foot manufacturing facility and also owns 82 hectares of arable land, located, Porto Allegre, Brazil. Millenia will use the Brazilian facility for the production of Malarex.
Cibecol, which has been in business for over 20 years, operates one of the largest phyto-pharmaceutical plants in southern Brazil. In addition to producing voacamine, the active agent in Malarex, Cibecol would continue to produce its own group of 61 natural medicines that are currently being Marketed in Brazil. This acquisition would be a key step forward toward Millenia's goal of becoming a vertically integrated producer and distributor of Malarex.
Furthermore, Millenia, under the leadership of Dr. David Mulder, Millenia's Vice Chairman, and Dr. Rene Morel, a member of our scientific committee, expect to introduce a new concept which we call 02-IV, oxygenation of intravenous solutions. Intravenous solution recipients will now be able to derive a positive boost from the extra dose of oxygen delivered directly to their blood stream.
The North American intravenous solution market, per estimates of Frost & Sullivan, is approximately $1.3 billion and the rest of the international market is about an additional $1.5 billion.
On May 31, 2001, Millenia Hope and Liquid Asset Corp. signed a purchase agreement, the terms of which give Millenia the exclusive worldwide rights to oxygenate intravenous solutions until September 1, 2005 with an option to purchase these same rights for a further 5 year period. The purchase price for these rights to September 1, 2005 is $500,000 in cash, 6 million Millenia Hope common shares and 2 million non-registered common shares of Sword Comp-Soft Corp. that are owned by Millenia.
Millenia has come to an agreement to utilize the services of Ropack, an FDA approved, HACCP and cGMP Compliant and ISO 9002 certified corporation, to perform quality control and all encapsulating of MALAREX(TM), confirming to U.S. and Canadian manufacturing standards. Assure the highest possible level of quality via product analysis and homogeneity testing for MALAREX(TM). This manufacturing facility, fully adhering to the highest quality standards of good manufacturing procedures, gives credence and assurance of the purity and safety of our final product. Ropack is accredited by both the U.S. and Canadian armies.
Liquidity and cash flow needs of the company
From December 1st, 2002 to May 31, 2003 the company and its subsidiary until March 5, 2003, incurred operating and interest expenses in the amount of $224,416 while recording net cash revenues of $47,630. from June 1st, 2003 to November 30th, 2003, the fiscal year end, the company anticipates that its net cash flow needs, will be $250,000 primarily to cover day today operating expenses. These funds will be covered by revenue received and any shortfalls will be met by the officers and certain shareholders as previously outlined.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Leonard Stella
Chief Operating Officer
(514) 846-5757
E-mail: leostella@milleniahope.com
Web: www.milleniahope.com
Form 10-Q for MILLENIA HOPE INC
15-Jul-2003
Quarterly Report
Plan of Operation.
The following discussion should be read in conjunction with the financial statements and related notes which are included elsewhere in this prospectus. Statements made below which are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties including, but not limited to, general economic conditions and our ability to market our product.
The business objectives of Millenia are twofold. First and foremost is to establish MALAREX as an accepted control agent for the treatment and prevention of malaria throughout the world. Not only do we believe that MALAREX is an effective anti-malarial drug, it will also be made available at prices that are adapted to the realities of the third world market. The availability and pricing of MALAREX, we believe, will ensure its acceptability and use in the fight against malaria. To this end the company is involved with ongoing clinical trials of MALAREX. As of February 28, 2003, Millenia Hope had received 8 sales authorizations from West African nations, Congo (Brazzaville) and Guinea (Conakry), Togo, Burundi, Central African Republic, Benin, Gabon and Chad. We are awaiting sales authorizations from several other West African nations. Based on managements best estimates, Millenia hopes to sell up to 1 million treatments of Malarex or $7 million worth, by the end of fiscal 2003.
Millenia has adopted an extremely conservative sales forecast. In the face of anti-malarial drug resistance, the need for more effective treatments will continue to intensify. Once a network of local manufacturers and distributors capable of producing and supplying MALAREX are in place, the demand for MALAREX should increase commensurately.
It is estimated the demand for MALAREX will increase as it becomes one of the accepted choices in the fight against malaria. Millenia has chosen to remain conservative and has established a goal of capturing 2% ($200 million) of the marketplace in five years. According to the company's internal estimates, based upon it's knowledge of the industry, attaining this sales level will ensure the viability and profitability of the Company for its shareholders. No assurance can be given that the Company will meet its sales goals.
Secondly, Millenia is committed to ongoing research and development to expand the efficacy of MALAREX and its derivatives in fighting infectious diseases. As the company has not yet made any significant sales of its product, it is difficult for management to evaluate the growth curve of Product sales. However, given the market size and the need for viable and effective drugs, the Company believes that it will not have a problem generating sales thereby creating positive cash flow once further authorizations have been obtained.
On May 29, 2000, the company acquired thirty five million seven hundred thousand (35,700,000) shares of SWORD COMP-SOFT CORP., this being 76.5% of SWORD's issued capital, at a cost of five million (5,000,000) common shares, and five million warrants (5,000,000), entitling the registered holder thereof to purchase at any time from that date for a period of three (3) years, one share of common stock at a price of two dollars ($2).
SWORD COMP-SOFT CORP. was an (ASP) Application Service Provider incorporated in November 1998 specializing in the E-Healthcare sector.
Application services, a rapidly growing segment of the Internet economy, are those that focus on a single topic or issue in a conversational manner. Essentially, the subscribers use application programs to create, store and transact medical data on the application server, for example, the interactive on-line health service will record similar data to that usually given to a primary health care worker, such as a doctor or a nurse,, and create an overall profile of individual health needs. Each application will relate to a specific disease, drug, or part of the human anatomy on a pay per use basis ( although this fee may be sponsored).
On March 5, 2003, Millenia divested its entire holding in Sword Comp-Soft, this being 30.7 million common shares. The aforementioned shares were tendered back to Sword Comp-Soft. In exchange for said 30.7 million shares, Sword Comp-Soft paid Millenia Hope $700,000 U.S., due within 12 months from the date of its signing of the agreement and gave Millenia its Medico Center site, Medico Research, any other related Medico
ASP work and all the attended backup documentation, computer line code etc., all is per the agreement signed on March 5, 2003.
The acquisition of Sword`s medical ASP's and Medico Records accessible on the Internet, where 45% of all inquiries are health related, is highly beneficial, as Millenia's scientific advisory committee, comprised of M.D.s and P.H.D.s with a wide range of expertise, will lend valuable assistance as we strive to bring to the market medical ASPs. Further, their breadth of knowledge and varied specializations should help to generate ideas and data to aid in the production of other medical ASP's.
On October 10, 2001 Millenia Hope and Cibecol Industrial Farmaceutica Ltda. Signed a purchase agreement via which Millenia will acquire 68% of the assets of Cibecol for $500,000 in cash, 7 million shares of Millenia Hope common shares and 1 million common shares of Sword Comp-Soft., a subsidiary of Millenia Hope, that are owned by Millenia.
Cibecol, incorporated and headquartered in Brazil, operates a 20,000 square foot manufacturing facility and also owns 82 hectares of arable land, located, Porto Allegre, Brazil. Millenia will use the Brazilian facility for the production of Malarex.
Cibecol, which has been in business for over 20 years, operates one of the largest phyto-pharmaceutical plants in southern Brazil. In addition to producing voacamine, the active agent in Malarex, Cibecol would continue to produce its own group of 61 natural medicines that are currently being Marketed in Brazil. This acquisition would be a key step forward toward Millenia's goal of becoming a vertically integrated producer and distributor of Malarex.
Furthermore, Millenia, under the leadership of Dr. David Mulder, Millenia's Vice Chairman, and Dr. Rene Morel, a member of our scientific committee, expect to introduce a new concept which we call 02-IV, oxygenation of intravenous solutions. Intravenous solution recipients will now be able to derive a positive boost from the extra dose of oxygen delivered directly to their blood stream.
The North American intravenous solution market, per estimates of Frost & Sullivan, is approximately $1.3 billion and the rest of the international market is about an additional $1.5 billion.
On May 31, 2001, Millenia Hope and Liquid Asset Corp. signed a purchase agreement, the terms of which give Millenia the exclusive worldwide rights to oxygenate intravenous solutions until September 1, 2005 with an option to purchase these same rights for a further 5 year period. The purchase price for these rights to September 1, 2005 is $500,000 in cash, 6 million Millenia Hope common shares and 2 million non-registered common shares of Sword Comp-Soft Corp. that are owned by Millenia.
Millenia has come to an agreement to utilize the services of Ropack, an FDA approved, HACCP and cGMP Compliant and ISO 9002 certified corporation, to perform quality control and all encapsulating of MALAREX(TM), confirming to U.S. and Canadian manufacturing standards. Assure the highest possible level of quality via product analysis and homogeneity testing for MALAREX(TM). This manufacturing facility, fully adhering to the highest quality standards of good manufacturing procedures, gives credence and assurance of the purity and safety of our final product. Ropack is accredited by both the U.S. and Canadian armies.
Liquidity and cash flow needs of the company
From December 1st, 2002 to May 31, 2003 the company and its subsidiary until March 5, 2003, incurred operating and interest expenses in the amount of $224,416 while recording net cash revenues of $47,630. from June 1st, 2003 to November 30th, 2003, the fiscal year end, the company anticipates that its net cash flow needs, will be $250,000 primarily to cover day today operating expenses. These funds will be covered by revenue received and any shortfalls will be met by the officers and certain shareholders as previously outlined.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Leonard Stella
Chief Operating Officer
(514) 846-5757
E-mail: leostella@milleniahope.com
Web: www.milleniahope.com
Form 10KSB/A for MILLENIA HOPE INC
22-Apr-2003
Annual Report
Item 6. Management's Discussion and Analysis of Financial Condition and OPERATIONS.
Special Note Regarding Forward-Looking Statements
Some of the statements under "Plan of Operations," "Business" and elsewhere in this registration statement are forward-looking statements that involve risks and uncertainties. These forward-looking statements include statements about our plans, objectives, expectations, intentions and assumptions and other statements contained herein that are not statements of historical fact. You can identify these statements by words such as "may," "will," "should," "estimates," "plans," "expects," "believes," "intends" and similar expressions. We cannot guarantee future results, levels of activity, performance or achievements. Our actual results and the timing of certain events may differ significantly from the results discussed in the forward-looking statements. You are cautioned not to place undue reliance on any forward-looking statements.
Plan of Operation.
The following discussion should be read in conjunction with the financial statements and related notes which are included elsewhere in this prospectus. Statements made below which are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties including, but not limited to, general economic conditions and our ability to market our product.
The business objectives of Millenia are twofold. First and foremost is to establish MALAREX as an accepted control agent for the treatment and prevention of malaria throughout the world. Not only do we believe that MALAREX is an effective anti-malarial drug, it will also be made available at prices that are adapted to the realities of the third world market. The availability and pricing of MALAREX, we believe, will ensure its acceptability and use in the fight against malaria. To this end the company is involved with ongoing clinical trials of MALAREX. As of February 28, 2003, Millenia Hope had received 8 sales authorizations from West African nations, Congo (Brazzavile) and Guinea (Conakry), Togo, Benin, Burundi, Central African Republic, Benin, Gabon and Chad. We are awaiting sales authorizations from several other West African nations. Based on managements best estimates, Millenia hopes to sell up to 1 million treatments of Malarex or $7 million worth, by the end of fiscal 2003.
Millenia has adopted an extremely conservative sales forecast. In the face of anti-malarial drug resistance, the need for more effective treatments will continue to intensify. Once a network of local manufacturers and distributors capable of producing and supplying MALAREX are in place, the demand for MALAREX should increase commensurately.
It is estimated the demand for MALAREX will increase as it becomes one of the accepted choices in the fight against malaria. Millenia has chosen to remain conservative and has established a goal of capturing 2% ($200 million) of the marketplace in five years. According to the company's internal estimates, based upon it's knowledge of the industry, attaining this sales level will ensure the viability and profitability of the Company for its shareholders. No assurance can be given that the Company will meet its sales goals.
Secondly, Millenia is committed to ongoing research and development to expand the efficacy of MALAREX and its derivatives in fighting infectious diseases. As the company has not yet made any significant sales of its product, it is difficult for management to evaluate the growth curve of Product sales. However, given the market size and the need for viable and effective drugs, the Company believes that it will not have a problem generating sales thereby creating positive cash flow once further authorizations have been obtained.
On May 29, 2000, the company acquired thirty five million seven hundred thousand (35,700,000) shares of SWORD COMP-SOFT CORP., this being 76.5% of SWORD's issued capital, at a cost of five million (5,000,000) common shares, and five million warrants (5,000,000), entitling the registered holder thereof to purchase at any time from that date for a period of three (3) years, one share of common stock at a price of two dollars ($2).
SWORD COMP-SOFT CORP. was an (ASP) Application Service Provider incorporated in November 1998 specializing in the E-Healthcare sector.
Application services, a rapidly growing segment of the Internet economy, are those that focus on a single topic or issue in a conversational manner. Essentially, the subscribers use application programs to create, store and transact medical data on the application server, for example, the interactive on-line health service will record similar data to that usually given to a primary health care worker, such as a doctor or a nurse,, and create an overall profile of individual health needs. Each application will relate to a specific disease, drug, or part of the human anatomy on a pay per use basis ( although this fee may be sponsored).
On March 5, 2003, Millenia divested its entire holding in Sword Comp-Soft, this being 30.7 million common shares. The aforementioned shares were tendered back to Sword Comp-Soft. In exchange for said 30.7 million shares, Sword Comp-Soft paid Millenia Hope $700,000 U.S., due within 12 months from the date of its signing of the agreement and gave Millenia its Medico Center site, Medico Research, any other related Medico ASP work and all the attended backup documentation, computer line code etc., all as per the agreement signed on March 5, 2003.
The acquisition of Sword's medical ASP's and Medico Records accessible on the Internet, where 45% of all inquiries are health related, is highly beneficial, as Millenia's scientific advisory committee, comprised of M.D.s and P.H.D.s with a wide range of expertise, will lend valuable assistance as we strive to bring to the market medical ASPs. Further, their breadth of knowledge and varied specializations should help to generate ideas and data to aid in the production of other medical ASP's.
On October 9, 2001 Millenia Hope and Cibecol Industrial Farmaceutica Ltda. Signed a purchase agreement via which Millenia will acquire 68% of the assets of Cibecol for $500,000 in cash, 7 million shares of Millenia Hope common shares and 1 million common shares of Sword Comp-Soft., a subsidiary of Millenia Hope, that are owned by Millenia.
Cibecol, incorporated and headquartered in Brazil, operates a 20,000 square foot manufacturing facility and also owns 82 hectares of arable land, located, Porto Allegre, Brazil. Millenia will use the Brazilian facility for the production of Malarex.
Cibecol, which has been in business for over 20 years, operates one of the largest phyto-pharmaceutical plants in southern Brazil. In addition to producing voacamine, the active agent in Malarex, Cibecol would continue to produce its own group of 61 natural medicines that are currently being Marketed in Brazil. This acquisition would be a key step forward toward Millenia's goal of becoming a vertically integrated producer and distributor of Malarex.
Furthermore, Millenia, under the leadership of Dr. David Mulder, Millenia's Vice Chairman, and Dr. Rene Morel, a member of our scientific committee, expect to introduce a new concept which we call 02-IV, oxygenation of intravenous solutions. Intravenous solution recipients will now be able to derive a positive boost from the extra dose of oxygen delivered directly to their blood stream.
The North American intravenous solution market, per estimates of Frost & Sullivan, is approximately $1.3 billion and the rest of the international market is about an additional $1.5 billion.
On May 31, 2001, Millenia Hope and Liquid Asset Corp. signed a purchase agreement, the terms of which give Millenia the exclusive worldwide rights to oxygenate intravenous solutions until September 1, 2005 with an option to purchase these same rights for a further 5 year period. The purchase price for these rights to September 1, 2005 is $500,000 in cash, 6 million Millenia Hope common shares and 2 million non-registered common shares of Sword Comp-Soft Corp. that are owned by Millenia.
Millenia has come to an agreement to utilize the services of Ropack, an FDA approved, HACCP and cGMP Compliant and ISO 9002 certified corporation, to perform quality control and all encapsulating of MALAREX(TM), confirming to U.S. and Canadian manufacturing standards. Assure the highest possible level of quality via product analysis and homogeneity testing for MALAREX(TM). This manufacturing facility, fully adhering to the highest quality standards of good manufacturing procedures, gives credence and assurance of the purity and safety of our final product. Ropack is accredited by both the U.S. and Canadian armies.
Year ended November 30, 2002 Compared to Year Ended November 30, 2001.
Total revenue for 2002 was $362,599 and had associated direct costs of $165,799 compared to $378,625 in revenue for the same period in 2001 and associated costs of $205,410. The drop in revenue is directly attributable to our having had an $81,000 sale of Malarex(TM) in 2001 and no sale in 2002. Our consulting revenue in Sword grew from 2001 to 2002.
Selling, general and administrative and amortization expenses were $137,635 for the year 2001. This represented an increase of $60,978 to $198,613 for 2002. This increase was attributable to the higher costs associated with office and professional fees. In 2002 we took a bad debt provision against Sword and Millenia accounts and notes receivable of $ 249,377. 2001 had no provision taken.
We incurred other development costs of $585,056 during 2001 as compared to $59,606 for the year 2002. This represents the purchase of commercializing rights to oxygenate intravenous solutions in 2001 as opposed to patents and development costs in 2002.
We had marketing expenses of $443,838 in year 2002 and $57,951 in 2001. We had increased expenses due to our seeking greater exposure in the business and investment communities.
In 2002, we wrote off our investment in Cibecol Farmaceutica pursuant to our assets not being legally registered in Millenia's Corporate name. This caused a $2,799,999 expense in 2002 that did not appear in 2001.
As a result of the foregoing we incurred a net loss of $3,591,729 for the year 2002, compared to a loss of $693,213 for the year 2001.
Liquidity and Capital Resources
Net cash used in financing operating and investing activities from December 01, 2001, through November 30, 2002, was $0. At November 30, 2002, we had an accumulated deficit from operating activities of $2,407,099.
Effect of Recent Accounting Pronouncements
In June 1998, the Financial Accounting Standards Board issued SFAS No. 133 "Accounting for Derivative Instruments and Hedging Activities," which requires entities to recognize all derivative financial instruments as either assets or liabilities in the balance sheet and measure these instruments at fair value. SFAS No. 133, as amended by SFAS No. 137, is effective for all fiscal years beginning after June 15, 2000. We do not presently enter into any transactions involving derivative financial instruments and, accordingly, we do not anticipate that the new standard will have any effect on our financial statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Leonard Stella
Chief Operating Officer
(514) 846-5757
E-mail: leostella@milleniahope.com
Web: www.milleniahope.com
Form 10-Q/A for MILLENIA HOPE INC
22-Apr-2003
Quarterly Report
Item 2. Plan of Operations
The following discussion should be read in conjunction with the financial statements and related notes which are included elsewhere in this prospectus. Statements made below which are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties including, but not limited to, general economic conditions and our ability to market our product.
The business objectives of Millenia are twofold. First and foremost is to establish MALAREX as an accepted control agent for the treatment and prevention of malaria throughout the world. Not only do we believe that MALAREX is an effective anti-malarial drug, it will also be made available at prices that are adapted to the realities of the third world market. The availability and pricing of MALAREX, we believe, will ensure its acceptability and use in the fight against malaria. To this end the company is involved with ongoing clinical trials of MALAREX. As of February 28, 2003, Millenia Hope had received 8 sales authorizations from West African nations, Congo (Brazzaville) and Guinea (Conakry), Togo, Burundi, Central African Republic, Benin, Gabon and Chad. We are awaiting sales authorizations from several other West African nations. Based on managements best estimates, Millenia hopes to sell up to 1 million treatments of Malarex or $7 million worth, by the end of fiscal 2003.
Millenia has adopted an extremely conservative sales forecast. In the face of anti-malarial drug resistance, the need for more effective treatments will continue to intensify. Once a network of local manufacturers and distributors capable of producing and supplying MALAREX are in place, the demand for MALAREX should increase commensurately.
It is estimated the demand for MALAREX will increase as it becomes one of the accepted choices in the fight against malaria. Millenia has chosen to remain conservative and has established a goal of capturing 2% ($200 million) of the marketplace in five years. According to the company's internal estimates, based upon it's knowledge of the industry, attaining this sales level will ensure the viability and profitability of the Company for its shareholders. No assurance can be given that the Company will meet its sales goals.
Secondly, Millenia is committed to ongoing research and development to expand the efficacy of MALAREX and its derivatives in fighting infectious diseases. As the company has not yet made any significant sales of its product, it is difficult for management to evaluate the growth curve of Product sales. However, given the market size and the need for viable and effective drugs, the Company believes that it will not have a problem generating sales thereby creating positive cash flow once further authorizations have been obtained.
On May 29, 2000, the company acquired thirty five million seven hundred thousand (35,700,000) shares of SWORD COMP-SOFT CORP., this being 76.5% of SWORD's issued capital, at a cost of five million (5,000,000) common shares, and five million warrants (5,000,000), entitling the registered holder thereof to purchase at any time from that date for a period of three (3) years, one share of common stock at a price of two dollars ($2).
SWORD COMP-SOFT CORP. was an (ASP) Application Service Provider incorporated in November 1998 specializing in the E-Healthcare sector.
Application services, a rapidly growing segment of the Internet economy, are those that focus on a single topic or issue in a conversational manner. Essentially, the subscribers use application programs to create, store and transact medical data on the application server, for example, the interactive on-line health service will record similar data to that usually given to a primary health care worker, such as a doctor or a nurse,, and create an overall profile of individual health needs. Each application will relate to a specific disease, drug, or part of the human anatomy on a pay per use basis ( although this fee may be sponsored).
On March 5, 2003, Millenia divested its entire holding in Sword Comp-Soft, this being 30.7 million common shares. The aforementioned shares were tendered back to Sword Comp-Soft. In exchange for said 30.7 million shares, Sword Comp-Soft paid Millenia Hope $700,000 U.S., due within 12 months from the date of its signing of the agreement and gave Millenia its Medico Center site, Medico Research, any other related Medico
ASP work and all the attended backup documentation, computer line code etc., all is per the agreement signed on March 5, 2003.
The acquisition of Sword`s medical ASP's and Medico Records accessible on the Internet, where 45% of all inquiries are health related, is highly beneficial, as Millenia's scientific advisory committee, comprised of M.D.s and P.H.D.s with a wide range of expertise, will lend valuable assistance as we strive to bring to the market medical ASPs. Further, their breadth of knowledge and varied specializations should help to generate ideas and data to aid in the production of other medical ASP's.
On October 10, 2001 Millenia Hope and Cibecol Industrial Farmaceutica Ltda. Signed a purchase agreement via which Millenia will acquire 68% of the assets of Cibecol for $500,000 in cash, 7 million shares of Millenia Hope common shares and 1 million common shares of Sword Comp-Soft., a subsidiary of Millenia Hope, that are owned by Millenia.
Cibecol, incorporated and headquartered in Brazil, operates a 20,000 square foot manufacturing facility and also owns 82 hectares of arable land, located, Porto Allegre, Brazil. Millenia will use the Brazilian facility for the production of Malarex.
Cibecol, which has been in business for over 20 years, operates one of the largest phyto-pharmaceutical plants in southern Brazil. In addition to producing voacamine, the active agent in Malarex, Cibecol would continue to produce its own group of 61 natural medicines that are currently being Marketed in Brazil. This acquisition would be a key step forward toward Millenia's goal of becoming a vertically integrated producer and distributor of Malarex.
Furthermore, Millenia, under the leadership of Dr. David Mulder, Millenia's Vice Chairman, and Dr. Rene Morel, a member of our scientific committee, expect to introduce a new concept which we call 02-IV, oxygenation of intravenous solutions. Intravenous solution recipients will now be able to derive a positive boost from the extra dose of oxygen delivered directly to their blood stream.
The North American intravenous solution market, per estimates of Frost & Sullivan, is approximately $1.3 billion and the rest of the international market is about an additional $1.5 billion.
On May 31, 2001, Millenia Hope and Liquid Asset Corp. signed a purchase agreement, the terms of which give Millenia the exclusive worldwide rights to oxygenate intravenous solutions until September 1, 2005 with an option to purchase these same rights for a further 5 year period. The purchase price for these rights to September 1, 2005 is $500,000 in cash, 6 million Millenia Hope common shares and 2 million non-registered common shares of Sword Comp-Soft Corp. that are owned by Millenia.
Millenia has come to an agreement to utilize the services of Ropack, an FDA approved, HACCP and cGMP Compliant and ISO 9002 certified corporation, to perform quality control and all encapsulating of MALAREX(TM), confirming to U.S. and Canadian manufacturing standards. Assure the highest possible level of quality via product analysis and homogeneity testing for MALAREX(TM). This manufacturing facility, fully adhering to the highest quality standards of good manufacturing procedures, gives credence and assurance of the purity and safety of our final product. Ropack is accredited by both the U.S. and Canadian armies.
Liquidity and cash flow needs of the company
From December 1st, 2002 to February 28, 2003 the company and its subsidiary incurred operating and interest expenses in the amount of $129,914 while recording net cash revenues of $47,630. from March 1st, 2003 to November 30th, 2003, the fiscal year end, the company anticipates that its net cash flow needs, will be $650,000 primarily to cover day today operating expenses. These funds will be covered by revenue received and any shortfalls will be met by the officers and certain shareholders as previously outlined.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Leonard Stella
Chief Operating Officer
(514) 846-5757
E-mail: leostella@milleniahope.com
Web: www.milleniahope.com
Form 10-Q for MILLENIA HOPE INC
16-Apr-2003
Quarterly Report
Item 2. Plan of Operations
The following discussion should be read in conjunction with the financial statements and related notes which are included elsewhere in this prospectus. Statements made below which are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties including, but not limited to, general economic conditions and our ability to market our product.
The business objectives of Millenia are twofold. First and foremost is to establish MALAREX as an accepted control agent for the treatment and prevention of malaria throughout the world. Not only do we believe that MALAREX is an effective anti-malarial drug, it will also be made available at prices that are adapted to the realities of the third world market. The availability and pricing of MALAREX, we believe, will ensure its acceptability and use in the fight against malaria. To this end the company is involved with ongoing clinical trials of MALAREX. As of February 28, 2003, Millenia Hope had received 8 sales authorizations from West African nations, Congo (Brazzaville) and Guinea (Conakry), Togo, Burundi, Central African Republic, Benin, Gabon and Chad. We are awaiting sales authorizations from several other West African nations. Based on managements best estimates, Millenia hopes to sell up to 1 million treatments of Malarex or $7 million worth, by the end of fiscal 2003.
Millenia has adopted an extremely conservative sales forecast. In the face of anti-malarial drug resistance, the need for more effective treatments will continue to intensify. Once a network of local manufacturers and distributors capable of producing and supplying MALAREX are in place, the demand for MALAREX should increase commensurately.
It is estimated the demand for MALAREX will increase as it becomes one of the accepted choices in the fight against malaria. Millenia has chosen to remain conservative and has established a goal of capturing 2% ($200 million) of the marketplace in five years. According to the company's internal estimates, based upon it's knowledge of the industry, attaining this sales level will ensure the viability and profitability of the Company for its shareholders. No assurance can be given that the Company will meet its sales goals.
Secondly, Millenia is committed to ongoing research and development to expand the efficacy of MALAREX and its derivatives in fighting infectious diseases. As the company has not yet made any significant sales of its product, it is difficult for management to evaluate the growth curve of Product sales. However, given the market size and the need for viable and effective drugs, the Company believes that it will not have a problem generating sales thereby creating positive cash flow once further authorizations have been obtained.
On May 29, 2000, the company acquired thirty five million seven hundred thousand (35,700,000) shares of SWORD COMP-SOFT CORP., this being 76.5% of SWORD's issued capital, at a cost of five million (5,000,000) common shares, and five million warrants (5,000,000), entitling the registered holder thereof to purchase at any time from that date for a period of three (3) years, one share of common stock at a price of two dollars ($2).
SWORD COMP-SOFT CORP. was an (ASP) Application Service Provider incorporated in November 1998 specializing in the E-Healthcare sector.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Leonard Stella
Chief Operating Officer
(514) 846-5757
E-mail: leostella@milleniahope.com
Web: www.milleniahope.com
Sword Host Releases Redesigned Website
Upgraded Site Offers Easier Accessibility And More Features
MONTREAL, CANADA --(INTERNET WIRE)--Oct 30, 2002 -- SWORD COMP-SOFT CORP., a SUBSIDIARY OF MILLENIA HOPE INC. (OTCBB: MLHP, BERLIN STOCK EXCHANGE MLF), has re-launched its premier hosting venue www.swordhost.com. Now entering its 3rd successful year, we have made the site even more user friendly and expanded its capacity to better serve our clients.
Our improved site now offers web hosting, website management, domain registration, website design services and secure certificates. Enhanced firewall protection, real time support and competitive pricing make us a favorite with current and future clients.
"By adding features, including 2 new hosting packages, and improving readability and ease of use, we have made Sword Host a consumer favorite, poised for even greater future growth," stated Anthony Ierfino, President and CEO.
About Sword Comp-Soft
Sword Comp-Soft Corp. is an Application Service Provider in the interactive health field on the Internet. Its goal is to offer knowledge and service databases, in lay terms, to allow the consumer to make educated choices in the area of health care. Health information on-line is a rapidly growing segment of the health care industry, whose sales are predicted to rise to $10 billion by the year 2004.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Sword Comp-Soft that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Sword Comp-Soft could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
Contact: Anthony Ierfino
Company: Sword Comp-Soft Corp.
Title: President and CEO
Voice: 514-821-5151
Email: anthony@swordcompsoft.com
URL: http://www.swordcompsoft.com
MILLENIA HOPE INVOLVED IN DEVELOPMENT OF A PROMISING LEISHMANIA TREATMENT
MONTREAL, CANADA (October 11, 2002) Millenia Hope Inc., a Biotech Corporate (OTC:BB-MLHP) (Berlin Stock Exchange – MLF) is pleased to announce its involvement with a team of scientists, lead by Dr. Celestino Di Flumeri, working on an a promising treatment that has shown positive results against Leishmania.
The company also announced that, as of October 8, 2002, it has discontinued its due diligence on a previously announced neutraceutical osteoporosis treatment. Due to Millenia not being provided with sufficient verifiable scientific data on the treatment, the preliminary distribution agreement will not be finalized and is terminated as of now.
As per the World Health Organization (WHO), Leishmaniasis is endemic in 88 countries with a total of 350 million people at risk of contracting this insidious disease. 12 million people have already been affected and between 1.5 and 2 million new cases are now occurring every year. Furthermore; the WHO considers the Leishmania/HIV co-infection as a real threat in Southwestern Europe.
"As part of our corporate mission, we are excited to be a part of the work on a treatment for this highly infectious disease", stated Dominique Morisot, President and CEO.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forwarding-looking statements". Several important factors could cause actual results to differ materially from those in such forwards-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Dominique Morisot
President and CEO
Millenia Hope Inc.
Tel: (514) 846-5757
E-mail: admin@milleniahope.com
Web site: www.milleniahope.com
Millenia Hope Receives Selling Authorization for Malarex From the Republic of Central Africa
Business Editors/Health & Medical Writers
MONTREAL--(BUSINESS WIRE)--Sept. 25, 2002--Millenia Hope Inc., a Biotech Corporation (OTC:BB-MLHP) (Berlin Stock Exchange - MLF), is pleased to announce that, following the reception of selling authorizations from the Republics of Guinea (Conakry) - certificate number: 253 MS-DNPL-SGG, Congo (Brazzaville) - certificate number: 0-165 MSSAH-DGS-SPHL-M-SA, Togo - certificate number 0266-02-MS-ASPFPE-DES-DPLET and Burundi - certificate number 31571325, we have received a selling authorization for Malarex(TM) from the Republic of Central Africa.
"Millenia's goal of having Malarex(TM) receive selling authorizations throughout all of West Africa is gaining momentum. This augers well for Millenia in reaching its sales target," said Dr George Tsoukas, Chairman of the Board.
About Millenia Hope:
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements". Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
CONTACT:
MILLENIA HOPE'S MALAREXtm'S FILE RECEIVES APPROVAL FROM BURUNDI.
MONTREAL, Canada (September 9th, 2002) - Millenia Hope Inc., a Biotech Corporation (MLHP-OTC:BB) (Berlin Stock Exchange - MLF), is pleased to announce that, following the reception of selling authorizations for the Republic of Guinea (Conakry), the Republic of Congo (Brazzaville), and the Republic of Togo, its selling authorization file has been approved by the country of Burundi under authorization # 31571325.
"Millenia Hope continues to gain momentum in its effort to bring its new anti-malarial agent, MalarexT, to the fight against this insidious disease", said Mr. Dominique Morisot, President. "We expect to make great progress, in the very near future, towards our goal of having MalarexT accepted in all of West Africa".
About Millenia Hope:
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia
Hope that may be referred to as "forward-looking statements". Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Mr. Dominique Morisot
President
Millenia Hope Inc.
Tel: (514) 846-5757
E-mail: dmorisot@milleniahope.com
Web site: www.milleniahope.com
Millenia Hope Inc. Retains Renmark Financial Communications Inc as its Investor Relations Advisor
MONTREAL, March 5 /PRNewswire-FirstCall/ - Millenia Hope Inc., a Biotech Corporation, (OTCBB:MLHP) (Berlin Stock Exchange-MLF) announced today that it has retained the services of Renmark Financial Communications Inc. ("Renmark") as their investor relations firm. Renmark is a well-known Investor Relations firm located in Montreal, Quebec.
Dominique Morisot, President and CEO of Millenia Hope commented, "We are pleased to announce the selection of Renmark Financial Communications as our investor relations advisor. We feel that Renmark can help increase Millenia Hope's visibility within the financial community."
ABOUT MILLENIA HOPE
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
SAFE HARBOUR STATEMENT
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forwarding-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
SOURCE Millenia Hope Inc.
-0- 03/05/2002
CONTACT: Barry Mire, Renmark Financial Communications Inc., (514) 939-3989, Fax: (514) 939-3717, bmire@renmarkfinancial.com; Sylvain Archambault, Renmark Financial Communications Inc., (514) 939-3989, Fax: (514) 939-3717, sarchambault@renmarkfinancial.com, www.renmarkfinancial.com/
DR. MSGR. ADDAI ADALBERT TH. JEGYUD, PROMINENT PHYSICIAN AND HUMANITARIAN, JOINS MILLENIA HOPE’S SCIENTIFIC COMMITTEE.
MONTREAL, CANADA (February 13, 2002) Mr. Dominique Morisot, President and CEO of Millenia Hope Inc. a Biotech Corporation, (OTCBB - MLHP) (the Berlin Stock Exchange - MLF), announced today the appointment of Dr. Msgr. Addai Adalbert Th. Jegyud OSA. M.D. KCCM. MOM. as a member of Millenia’s scientific and medical committee. Dr. Jegyud is a much honored Anaesthisit who has served as, amongst his numerous positions and functions, the chief of Anesthesia of Reddy Memorial Hospital as well as a longtime member of its Board of Directors, medical Director of the Catherine Booth Hospital where he was personally instrumental in establishing its internationally recognized Leprosy Research Center, physician of the palliative care ward of the Mount Sinai Hospital as well as its Orthodox Catholic Chapelin, etc.
Dr. Jegyud’s accomplishments both in the medical field and in humanitarian endeavors are too numerous to list. Establishment of the Reddy Memorial’s first walk-in pain clinic. His tireless work on behalf of the children injured during the war in the former Yugoslavia, including arranging to have them treated in Canada and then repatriating them to their homes, etc.
\"Having a person of the caliber of Dr. Jegyud join our scientific team is both a great honor and will lend invaluable assistance to Millenia Hope. Dr. Jegyud with his great medical skills and truly compassionate nature will surely aid our endeavors to bring Malarextm, our premier anti-malarial drug, to those nations desperately in need of fresh solutions to the scourge of malaria\", said Mr. Morisot.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as \"forwarding-looking statements\". Several important factors could cause actual results to differ materially from those in such forwards-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Dominique Morisot
President
Millenia Hope Inc.
Tel: (514) 846-5757
dmorisot@milleniahope.com
MALAREX™ VALIDATED AGAIN AS AN ANTI-MALARIAL AGENT
MALAREX™’S CURE RATE IS 100% IN PROFESSOR SAME EKOBO’S LATEST TEST
MONTREAL, CANADA (January 16, 2002) Millenia Hope Inc., a Biotech Corporation, (OTCBB – MLHP) (Berlin Stock Exchange-MLF) today released the results of tests done by Professor Same Ekobo, National Coordinator of Cameroun’s Anti-Malarial Program and Director of the Center for Parasite Research in Yaounde, Cameroun, West Africa.
His study covered 30 patients suffering from acute Falciparum Malaria, both male and female with the ages ranging from 4 years old to over 65 years of age. Within 4 days of the 5-day treatment regimen, 100% of the patients were cured of their malarial symptoms. The few side effects noticed were slight and went away almost immediately on their own. These were comprised of 1 case each of dizziness, headache and vomiting. 96.6% of these patients were found to be fit to take Malarex™ again should they incur another episode of malaria. These results are consistent with our other studies of Malarex™.
"Malarex™ is gaining an international reputation for its efficacy and safeness. Within a short span of time, this should translate into a larger sales volume as can be seen from yesterday’s announcement of our first substantial sales order", proclaimed Dominique Morisot, President and CEO of Millenia Hope.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forwarding-looking statements". Several important factors could cause actual results to differ materially from those in such forwards-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Dominique Morisot
President
Millenia Hope Inc.
Tel: (514) 846-5757
dmorisot@milleniahope.com
MILLENIA HOPE FINALIZES PROCESSING DEAL WITH ROPACK Canadian ISO 9002 Corporation to process and package MALAREX™
MONTREAL, CANADA (January 10, 2002) Millenia Hope Inc. (OTCBB – MLHP), a Biotech Corporation, also listed for trading on the Berliner Wertpapier Borse (the Berlin Stock Exchange – MLF) announced today that it is utilizing the services of Ropack, an FDA approved, HACCP and cGMP Compliant and ISO 9002 certified corporation for MALAREX™, Millenia’s flagship antimalarial drug. Ropack will perform the following procedures at its plant in Montreal, Canada. Control the quality of the raw material received from our Brazilian manufacturing facility. Mix, encapsulate and package MALAREX™, conforming to U.S. and Canadian manufacturing standards. Assure the highest possible level of quality via product analysis and homogeneity testing for MALAREX™. This manufacturing facility, fully adhering to the highest quality standards of good manufacturing procedures, will give credence and assurance of the purity and safety of our final product.
"Millenia is constantly striving to improve its practices to offer the best quality product that it can make. Ropack, a corporation accustomed to working at the highest standard of quality control and accredited by both the U.S. and Canadian armies, is one of the dimensions that is helping us to achieve this goal", said Dominique Morisot, President and CEO of Millenia Hope.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forwarding-looking statements". Several important factors could cause actual results to differ materially from those in such forwards-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Dominique Morisot
President
Millenia Hope Inc.
Tel: (514) 846-5757
dmorisot@milleniahope.com
MILLENIA HOPE, MAKER OF MALAREX™, HIRES EUROPEAN CONSULTANTS BALTIC INVESTMENTS TO RAISE CORPORATE AWARENESS IN EUROPE.
MONTREAL, CANADA (January 3, 2002) Millenia Hope Inc. a biotech corporation, listed for trading on the OTCBB (MLHP) and the Berliner Wertpapier Borse (the Berlin Stock Exchange) (MLF), has hired Baltic Investments, corporate consultants, to handle its European Investor Relations. The Company, which expects to be an active participant in the European markets, is seeking to strengthen and broaden its corporate profile in Europe.
"We are gearing up for the next growth stage of Millenia Hope", said Dominique Morisot, President and CEO of Millenia. "Millenia Hope is quickly maturing into a stable biotech player and we expect Baltic Investments to aid us in disseminating and sharing our corporate vision with our EuropeanInvestors."
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forwarding looking statements". Several important factors could cause actual results to differ materially from those in such forward looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Dominique Morisot
President Millenia Hope Inc.
Tel: (514) 846-5757 dmorisot@milleniahope.com
www.milleniahope.com
www.malarex.com
JEFFREY BROOKS JOINS MILLENIA HOPE
MONTREAL, CANADA (December 28, 2001) Millenia Hope Inc. (OTCBB - MLHP)(BWB-MLF), a biotech corporation, announced today that Mr. Jeffrey H. Brooks has joined the company as its Vice President of Operations.
Mr. Brooks, a biotech and pharmaceutical projects engineer, has a vast and varied knowledge of the pharmaceutical business, cutting a wide swath across some of the largest players in the industry. He has worked for and consulted to, among others, AHP Wyeth-Ayerst, Merck and Company, Abbot Laboratories Ltd, Connaught Laboratories Ltd. etc. A member of the International Society for Pharmaceutical Engineering, the Pharmaceutical Sciences Group and other professional associations, Mr. Brooks will be responsible for assuring the quality of MALAREX™, Millenia's flagship anti-malarial drug, as well as the products in the future, from the production stage through packaging and shipping to distribution to the end product recipient. He will also be one of the key personnel involved in our development of a Research and Development facility.
"Millenia is honoured and excited to have someone of the caliber of Jeffrey Brooks join its management. In our ongoing effort to make Millenia a leading edge biotech corporation, we have added an individual to our staff who brings years of experience and the depth of industry knowledge so crucial to our continued growth," said Dominique Morisot, President and CEO of Millenia Hope.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forwarding-looking statements". Several important factors could cause actual results to differ materially from those in such forwards-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
MILLENIA HOPE, MAKER OF MALAREX™, LISTED ON EUROPEAN STOCK MARKET ANTI-MALARIAL DRUG MANUFACTURER, TO BEGIN TRADING TODAY
MONTREAL, CANADA (December 11, 2001) As of December 10, 2001, Millenia Hope Inc. (OTCBB – MLHP), a biotech corporation, is listed for trading on the Berliner Wertpapier Borse, the Berlin Stock Exchange. Millenia Hope feels its stock will be actively traded under its new European trading symbol, MLF.
"Being listed on a European exchange is another important step forward for Millenia. The European Union is one of the world’s great economic centers and Millenia believes it will enjoy a profitable presence in that market", said Dominique Morisot, President and CEO of Millenia.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forwarding-looking statements". Several important factors could cause actual results to differ materially from those in such forwards-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Dominique Morisot
President
Millenia Hope Inc.
Tel: (514) 846-5757
dmorisot@milleniahope.com
MILLENIA HOPE, MAKER OF MALAREX™, ACTIVELY SEEKING EUROPEAN STOCK MARKET PRESENCE ANTI-MALARIAL DRUG MANUFACTURER, EXPECTS TO BE LISTED FOR TRADING IN EUROPE.
MONTREAL, CANADA (November 30, 2001) Millenia Hope Inc. (OTCBB – MLHP), a biotech corporation, is diligently working on being listed on one of the major European Stock Markets. Due to strongly perceived interest and their awareness of the malaria problem, Millenia feels it will be highly advantageous to be actively traded in Europe.
"Being listed on a European exchange would be a powerful strategic move for Millenia. The European Union is one of the world’s great economic centers and Millenia looks forward, with great anticipation, to being an active player there," said Dominique Morisot, President and CEO of Millenia.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forwarding-looking statements". Several important factors could cause actual results to differ materially from those in such forwards-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Dominique Morisot
President
Millenia Hope Inc.
Tel: (514) 846-5757
dmorisot@milleniahope.com
MILLENIA HOPE'S MALAREX™ RECEIVES SELLING AUTHORIZATION ANTI-MALARIAL DRUG, TO BE SOLD IN WEST AFRICA.\
MONTREAL, CANADA (October 18, 2001) - Millenia Hope Inc. (OTCBB - MLHP), a biotech corporation, is pleased to announce that it has received Sales and Distribution Visas from several African countries for its flagship anti-malarial drug Malarex™. The clearance, by the health authorities in those nations, means that Millenia will begin delivery of Malarex™ in the 4th quarter of this year. Millenia expects that its revenue stream will grow rapidly commencing with these first sales.
"We are very excited to be at the selling stage for Malarex™ . Reaching this key juncture will greatly aid us in the development and eventual sales of other promising products in our research pipeline", said Dominique Morisot, President and CEO of Millenia.
Millenia Hope is currently in the midst of further contract negotiations and fully expects to meet its forecast of selling 500,000 treatments by the end of 2001.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forwarding looking statements". Several important factors could cause actual results to differ materially from those in such forward looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Dominique Morisot,
President Millenia Hope Inc.
Tel: (514) 846-5757
dmorisot@milleniahope.com
www.MilleniaHope.com
www.malarex.com
SWORD COMP-SOFT CORP., A SUBSIDIARY OF MILLENIA HOPE, GIVEN FINAL CLEARANCE BY S.E.C. Corporation awaits NASD approval to be listed for trading
MONTREAL, Canada (July 24, 2001) – Millenia Hope ( OTC BB :MLHP) announced today that, as of July 16, 2001, its subsidiary Sword Comp-Soft Corp. had reached the no comment stage (final clearance) with the United States Securities Exchange Commission. This means that the Commission is satisfied with Sword’s public filing, its SB-2 registration statement, and has no further questions to pose to the corporation. As it is now a reporting company in good standing, Sword Comp-Soft Corp. has filed its 15C-211 with the NASD via one of its market makers. Once the NASD has cleared this filing, Sword will be able to be listed for public trading.
"This is very exciting news for shareholders of both Millenia Hope and Sword Comp-Soft Corp. Listing on the public markets should add great value to both corporations and is another step forward on the road to Millenia Hope’s future success", said Dominique Morisot, President and CEO of Millenia Hope Inc.
"We have great aspirations for the future for our shareholders and all our stakeholders," added Anthony Ierfino, President and CEO of Sword Comp-Soft Corp.
Sword Comp-Soft Corp. is an Application Service Provider in the interactive health field on the Internet. Its goal is to offer knowledge and service databases, in lay terms, to allow the consumer to make educated choices in the area of health care. Health information on-line is a rapidly growing segment of the health care industry, whose sales are predicted to rise to $10 billion by the year 2004.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Dominique Morisot
President
Millenia Hope Inc.
(514) 846-5757
E-Mail:dmorisot@milleniahope.com
Website:www.milleniahope.com
SWORD COMP-SOFT CORP., A SUBSIDIARY OF MILLENIA HOPE, GIVEN FINAL CLEARANCE BY S.E.C. Corporation awaits NASD approval to be listed for trading
MONTREAL, Canada (July 24, 2001) – Millenia Hope ( OTC BB :MLHP) announced today that, as of July 16, 2001, its subsidiary Sword Comp-Soft Corp. had reached the no comment stage (final clearance) with the United States Securities Exchange Commission. This means that the Commission is satisfied with Sword’s public filing, its SB-2 registration statement, and has no further questions to pose to the corporation. As it is now a reporting company in good standing, Sword Comp-Soft Corp. has filed its 15C-211 with the NASD via one of its market makers. Once the NASD has cleared this filing, Sword will be able to be listed for public trading.
"This is very exciting news for shareholders of both Millenia Hope and Sword Comp-Soft Corp. Listing on the public markets should add great value to both corporations and is another step forward on the road to Millenia Hope’s future success", said Dominique Morisot, President and CEO of Millenia Hope Inc.
"We have great aspirations for the future for our shareholders and all our stakeholders," added Anthony Ierfino, President and CEO of Sword Comp-Soft Corp.
Sword Comp-Soft Corp. is an Application Service Provider in the interactive health field on the Internet. Its goal is to offer knowledge and service databases, in lay terms, to allow the consumer to make educated choices in the area of health care. Health information on-line is a rapidly growing segment of the health care industry, whose sales are predicted to rise to $10 billion by the year 2004.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
For further information, contact:
Dominique Morisot
President
Millenia Hope Inc.
(514) 846-5757
E-Mail:dmorisot@milleniahope.com
Website:www.milleniahope.com
Millenia Hope Inc. to Help Build Hospitals Worldwide
MONTREAL, CANADA--Millenia Hope Inc., (OTCBB-MLHP), a Delaware Corporation, announced today that it has entered into a joint venture, with Nitra Inc. USA, to help build hospitals worldwide under the corporate name of Nitra Corporation of Canada.
Nitra Inc. USA's President, Marcel Niederhauser, was quoted as follows, "It is with great anticipation and pleasure that I look forward to working with a cutting edge biotech company like Millenia. The synergy created by our progressive construction methods and their scientific expertise should help cement a profitable union." Mr. Niederhauser has been involved in the building of hospitals around the globe for the past 30 years.
Dominique Morisot, Millenia's President, commented, "we are proud to be able to associate Millenia with Nitra and Mr. Niederhauser. Helping to build hospitals in the developing nations fits in perfectly with our goal of assisting third world countries with their medical needs."
Currently, the final phases of feaseability studies and financing methodologies, for new hospital construction, are under way in Ghana, Senegal and Mali.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatment and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts andexpectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter
unanticipated obstacles and delays in developing products, serviceofferings and markets.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Dominique Morisot
President
(514) 846-5757
E-Mail:dmorisot@milleniahope.com
Web Site: www.milleniahope.com
Millenia Hope Inc. Receives Exclusive Worldwide Distribution Rights for Oxygenated Intravenous Solution (02-Iv)
License for revolutionary way to deliver oxygen directly to the blood stream finalized.
MONTREAL, CANADA - Millenia Hope Inc. (OTC BB-MLHP), a Delaware Corporation, announced today that, as of this morning, it has agreed to a deal to acquire the exclusive license to sell oxygenated intravenous solution from Liquid Asset Corp.
The fluid-treatment technology used to produce 02-IV attaches oxygen to water, where it remains in a stable state over time. This technology was validated through tests at the laboratories ofthe Quebec government. Studies repeatedly showed that our treated water contained oxygen in concentrations of 20 parts per million (ppm) - the highest concentration detectable by the government laboratory's instruments. The company's own tests have confirmed oxygen concentrations exceeding 50 ppm, even six months after the water had been treated. In its natural state, water retains between 4.5 and 9.0 ppm of oxygen.
Recently completed animal studies have confirmed that the test subjects' venous oxygen levels were more than 50% - 100% higher then their normal blood levels. Increased oxygen provides humans with numerous benefits such as more cardiovascular endurance, higher levels of energy, improved concentration, a calmer nervous system and reduced toxin levels.
"We believe 02-IV will be particularly helpful for patients with heart or pulmonary problems and for ambulatory patients who cannot obtain additional oxygen through exercise," said Dominique Morisot, President of Millenia Hope. "We expect to carve out a profitable niche in the $2.8 billion intravenous market benefiting our shareholders and the public at large".
Human trials are slated to start by mid 2001 in Canada, Mexico and certain African countries. Depending on the pace of the tests and of regulatory approval, oxygenated intravenous solutions could be introduced to the North American market by 2002 and move onto world markets soon after.
02-IV is Millenia Hope's second product. The company's flagship product, Malarex, an effective, non-toxic treatment for malaria, is expected to be in production in 2001.
About Millenia Hope
Millenia Hope is in the business of developing innovative
treatment and quality medication products that will lead to
healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language
describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Dominique Morisot
President
(514) 846-5757
E-Mail: dmorisot@milleniahope.com
http://www.milleniahope.com
Millenia Hope Inc.: North American Validation For Malarex
MONTREAL, CANADA-Millenia Hope (OTCBB: MLHP) announced today that its flagship anti-malarial drug, MALAREX(TM), had shown excellent results in Canadian in-vitro testing. Drs. DiFlumeri and Schurr, of the Center for the Study of Host Resistance, McGill University Health Center, confirmed that, even at extremely low doses, MALAREX(TM), was able to cause a substantial decrease in the malaria parasite.
Ongoing testing is being done, in this North American trial, in order to compare the efficacy of MALAREX(TM) with respect to commonly used anti-malarial drugs such as chloroquine, mefloquine, and quinine. Also, in conjunction with Dr. Mary Stevenson of the Center for the Study of Host Resistance, in vivo trials have been initiated in animal models.
Malaria is a disease that kills up to 3 million people per year. Over 40% of the world's population is situated in areas in which the malaria parasite can be found. MALAREX(TM) has already been approved for consumer use by several African countries. Millenia is constantly looking to upgrade the efficacy of its premier anti-malarial drug.
"Since anti-malarial drug resistance is now the number one problem, bringing a potent new weapon to bear in the fight against malaria is very encouraging news," said Dominique Morisot, President of Millenia Hope.
For the complete text of the McGill University Health Center study please go to www.malarex.com.
About Millenia Hope
Millenia Hope Is in the business of developing innovative treatments and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement Certain statements made in this release may contain language describing the plans, goals, Strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forwarding-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Dominique Morisot
President
(514) 846-5757
dmorisot@milleniahope.com
MONTREAL, CANADA--Millenia Hope announced today that as of January 30, 2001, it had rejoined the OTC Bulletin Board. Having previously been accepted as a reporting company in good standing, by the SEC, Millenia Hope refiled its 15C-211 with the NASD via one of its market makers. The NASD has now cleared this filing and Millenia Hope will resume trading on the Over the Counter Bulletin Board and have its stock's bid and ask posted under its trading symbol MLHP. (Confirmation of this is on the NASD OTCBB website - www.otcbb.com)
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbour Statement
Certain statements made in this release may contain language describing the plans, goals, Strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forwarding-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Dominique Morisot
President
(514) 846-5757
dmorisot@milleniahope.com
MONTREAL, CANADA--Millenia Hope announced today that as of December 26, 2000 it had reached the no comment stage (final clearance) with the United States Securities Exchange Commission. This means that the Commission is satisfied with Millenia Hope's public filings, its 10SB registration statement, quarterly statements and 8K statement and has no further questions to pose to the corporation regarding the aforementioned statements. As it is now a reporting company in good standing, Millenia Hope has refiled its 15C-211 with the NASD via one of its market makers.
Once the NASD has cleared this filing, Millenia Hope will be able to rejoin the Over the Counter Bulletin Board and have its stock's bid and ask posted under its trading symbol MLHP.
"Millenia Hope always strives to give a complete and transparent view of its operations to its shareholders and the general public," said Dominique Morisot, President Millenia Hope.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forwarding-looking statements." Several important factors could cause actual results to differ materially from those in such
forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Dominique Morisot
President
(514) 846-5757
dmorisot@milleniahope.com
MONTREAL, CANADA--Millenia Hope (OTC: MLHP) announced today that it is investigating the development of oxygenated intravenous solution (O2-IV) for the global medical supplies market.
The fluid-treatment technology used to produce O2-IV attaches oxygen to water, where it remains in a stable state over time. Millenia Hope is investigating the potential to apply the patented technology to intravenous fluid, which is essentially a combination of water and salts or glucose.
"This radical advance, if validated, would provide hospitalized patients with an effective new source of oxygen, delivered directly to the bloodstream, providing them with additional strength and vigor," said Dominique Morisot, President of Millenia Hope. "Increased oxygen provides humans with numerous benefits such as cardiovascular endurance, raised energy levels, improved concentration, a calmer nervous system and reduced toxin levels. We believe O2-IV will be particularly helpful for patients with heart or pulmonary problems and for ambulatory patients who cannot obtain additional oxygen through exercise."
The technology, although new, was recently validated through tests at a Quebec government laboratory. Studies repeatedly showed that treated water contained oxygen in concentrations of 20 parts per million (ppm) - the highest concentration detectable by the government laboratory's instruments. The company's own tests have confirmed oxygen concentrations exceeding 50 ppm, even six months after the water had been treated. In its natural state, water retains between 4.5 and 9.0 ppm of oxygen.
Millenia Hope has also undertaken toxicity tests on O2-IV, which have confirmed that the technology is non-toxic. Pre-clinical animal studies, now underway in Montreal, have confirmed that test subjects that received oxygenated intravenous fluid had substantially elevated oxygen levels in their blood. These tests are being repeated to validate this conclusion.
Mr. Morisot added, "We will begin human trials by early 2001 and depending on the pace of the tests and of regulatory approvals, oxygenated intravenous solutions may enter the North American market by 2002 and move into world markets soon after."
O2-IV is Millenia Hope's second product. The company's flagship product is Malarex, an effective, non-toxic treatment for malaria, which it hopes to have in production in 2001.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatment and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Dominique Morisot
President
(514) 846-5757
E-mail: dmorisot@milleniahope.com
www.milleniahope.com
Millenia Hope Vertically Integrated with Brazilian Pharmaceutical Facility
MONTREAL, CANADA--Millenia Hope entered into the final stages of negotiation to acquire an interest in Cibecol Industrial Farmaceutica. Cibecol operates a 20,000 square foot manufacturing facility and 80 hectares of arable land in Porto Allegre, Brazil.
Millenia Hope said today it will use the Brazilian facility for the production of products such as Malarex, its flagship anti-malarial treatment. Malarex has exhibited positive results when used by malaria patients.
Cibecol operates one of the largest phyto-pharmaceutical plants in southern Brazil. In addition to voacamine, the active agent in Malarex, Cibecol will continue to produce its own group of 61 natural medicines that are currently marketed in Brazil.
"This acquisition is a key step toward our goal of becoming a vertically integrated producer and distributor of Malarex," said Dominique Morisot, President and CEO of Millenia Hope. He added: "We are also delighted that Mr. Faustino Bordignon has agreed to remain president of Cibecol, which he founded more than 20 years ago, once the acquisition is consummated."
Said Bordignon: "This investment by Millenia Hope would help Cibecol enter the global marketplace. We have been looking for the best way to bring our products to a larger market and MilleniaHope would be an ideal distribution partner. This move would also allow us to expand the sales of our natural medicines into several additional countries."
Malaria afflicts a large proportion of the human population. The World Health Organization has estimated that 500 million people a year acquire the disease and that it proves fatal for two million people a year.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatment and quality medication products that will lead to healthier lives.
Our focus is on research and development that brings healthcare solutions to meet global medical needs.
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts andexpectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
Millenia Hope (OTCBB:MLHP) announced today that its v Sword Comp-Soft Corp subsidiary has filed a Form SB-2 Registration Statement a with the U.S. Securities and Exchange Commission (SEC).
MONTREAL--Oct. 11, 2000--Millenia Hope (OTCBB:MLHP) announced today that its v Sword Comp-Soft Corp subsidiary has filed a Form SB-2 Registration Statement a with the U.S. Securities and Exchange Commission (SEC). If the registration statement is declared effective, Sword Comp-Soft will become a reporting issuer as per SEC regulations and will file quarterly and annual financial statements and all other relevant business information with the SEC.
The registration statement will also enable registered stockholders to sell their shares of the company's common stock for their own account in the open market or in private transactions at such prices as may be agreed upon. There is presently no public market for the company's securities, but Sword-Comp Soft intends to apply for a listing on small cap NASDAQ.
Dr. George M. Tsoukas, Chairman of Millenia Hope, said the filing takes Sword Comp-Soft another step closer to commencing operations. "Sword Comp-Soft is focused on applying technology to help meet consumers' informational needs and to refine their understanding and management of diseases such as osteoporosis and diabetes," he said. "Millenia Hope accepted the opportunity earlier this year to support Sword as its controlling shareholder, and we look forward to helping Sword reach its full potential."
The filed Form SB-2 statement is available for viewing on the company's Website at www.swordcompsoft.com.
About Sword-Comp Soft Corp.
Sword-Comp Soft Corp., based in Montreal, is a new Application Service Provider (ASP) that is developing a range of services around the concept of providing a series of useful, on-line interactive health services and facilities to individuals over the Internet. Essentially, subscribers create, store and transact medical data on the application server to create an overall profile of individual health needs. Each application will relate to a specific disease, drug or part of the human anatomy on a pay-per-use basis.
The first of the applications on which the Company intends to focus are the areas of nutrition, osteoporosis, diabetes and the human skeletal system. Consumers will be able to access the company's branded web site, www.medicocenter.com and receive an individualized assessment based on their current health level and a nutritional plan to enhance the quality of their life and well-being in the future. Safe Harbor Statement
The forward-looking statements in this news release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be significantly affected by certain risks and uncertainties described in the company's documents, as filed with the Securities and Exchange Commission.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service
offerings and markets.
FOR FURTHER INFORMATION PLEASE CONTACT:
Millenia Hope Inc.
Dominique Morisot
President
(514) 846-5757
E-mail: dmorisot@milleniahope.com
www.MilleniaHope.com
Malarex laboratory study successful; Millenia Hope prepares clinical trials for flagship anti-malarial product
MONTREAL, CANADA--Millenia Hope (OTC: MLHP) said today that tests on Malarex, its anti-malarial treatment, had produced no mortality or significant side effects in preclinical animal laboratory studies.
The company intends to schedule Phase 1 clinical trials in coming weeks, said Millenia Hope's Chairman, Dr. George M. Tsoukas.
The toxicity tests, carried out at FDA-approved facilities in Montreal, Canada, used doses as high as 100 times the usual dose without producing significant clinical side-effects in the laboratory animals used for the study.
"These results represent encouraging progress toward our objective of establishing that Malarex is a safe and efficient treatment for malaria," said Dr. Tsoukas. "We have also seen promising studies in humans, conducted by medical researchers in Cameroon and Mozambique. These results must be validated to the satisfaction of our scientific advisory committee."
Dr. Tsoukas added: "It is essential to us that the claims we make in support of Malarex be verifiable so that patients, physicians, purchasers and regulators may be satisfied that the product is safe and effective."
Malarex is derived from voacamine, a natural extract obtained from Pescheria fuchsiae folia, a tree found in Brazil. Malarex has exhibited positive results when administered to malaria patients. The disease affects as many as 500 million people each year and kills some three million of its victims.
Millenia Hope announced Tuesday that it has filed patent applications concerning voacamine in more than 50 countries. It already holds patent rights in Italy, where much of the voacamine-refining research has been conducted.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatment and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts andexpectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.
Millenia Hope Files Patent Requests For Malarex Ingredient
MONTREAL, CANADA--Millenia Hope Inc. (OTC: MLHP), announced today it has filed patent applications in 52 countries for the key ingredient in its flagship anti-malarial product sold as Malarex.
The company has filed patent applications in the United States, Canada, Europe, Japan, the states served by the European Patent Office, the African Regional Industrial Property Organization (ARIPO) and the African Intellectual Property Organization (OAPI),as well as Brazil, India, Mexico, South Africa, Vietnam, and Madagascar.
The patent applications announced today concern voacamine as an anti-malarial agent active against Plasmodium falciparum strains, including the resistant strains, as well as an anti-malarial agentcontaining voacamine as its main active principle. A basic Pescheria extract, in particular Pescheria fuchsiaefolia, can be used as an anti-malarial agent having voacamine as active principle.
Millenia Hope holds a voacamine patent already in Italy.
Malarex, which includes voacamine, has exhibited positive results when administered to malaria patients. The disease affects as many as 500 million people each year and kills some three million of its victims.
About Millenia Hope
Millenia Hope is in the business of developing innovative treatment and quality medication products that will lead to healthier lives.
Our people are committed to research and development to meet unmet medical needs globally and to bring hope through healthcare solutions.
Safe Harbor Statement
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts andexpectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.